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The increase in the number of fungal infections since the 1980s is a major concern 
globally. Fungal infections affect various medical and agricultural sectors. A limited number 
of available antifungal drugs in addition to the development of the antifungal drug 
resistance, urge the need for the development of new antifungal drugs. Candida albicans 
and Candida glabrata are the two most common causes of topical and systemic Candida 
infections, and specifically prone to drug resistance. Therefore, the next generation of 
antifungal drugs has to be compounds with a low probability to elicit resistance. The 
tyrocidines (Trcs) and analogues are cyclic decapeptides with a broad antimicrobial spectrum 
and proven anti-Candida activity. The development of resistance is less likely due to 
their rapid mode of action and multiple targets. The Trcs and analogues have a great 
tendency to oligomerise and the antimicrobial activity of the Trcs may be dependent on their 
ability to form active oligomers. In this study, we aimed to manipulate the Trc oligomerisation 
by combining it with cellulose derivatives as formulants. The goal was to increase the anti-
Candida activity as well as the stability of theses peptides in solution. Furthermore, if a 
concomitant decrease in the toxicity against human erythrocytes would also be beneficial. 
The oligomerisation profile of Trcs is driven by four main factors, namely, concentration, 
maturation time, peptide structure and the viscosity of the cellulose derivatives used in the 
formulation. The oligomerisation of Trcs is a dynamic arrangement and rearrangement of 
the peptide in the Trc mixture throughout the maturation period. For the more viscous 
cellulose-type formulants, this rearrangement resulted in the release of the more dimeric 
oligomers and increased the anti-Candida activity of the Trc mixture, However, for pure 
peptides such as TrcA and TpcC, both formulation and the maturation time did not alter 
the anti-Candida activity. This could be that TrcA oligomers are highly stable and maturation 
time does not result in releasing of more active moieties. Tic is inherently less active, and it 
may not have the optimal structure to interact with the Candida target. It was observed that a 
high concentration of cellulose derivatives significantly increased the anti-Candida activity of 
the Tic mixture, as well as stabilising the tic peptides in solutions, as detected with 
fluorescence. Unfortunately, none of the cellulose formulations of try mix decreased the 
haemolytic activity against human erythrocytes. However, anti-Candida activity was 

























Who does not know, and does not know that he does not know, 
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The significant increase in antimicrobial resistance is a global emergency as antimicrobial 
resistance can be life-threatening and can affect different life sectors such as the medical, 
industrial and agriculture sectors. Candida albicans (C. albicans) is a life-threatening 
yeast in immunocompromised individuals that can form biofilms on biotic surfaces, with 
reported resistance to its first-line treatment such as amphotericin B and fluconazole. 
Therefore, the development of new antifungals with anti-Candida activity is essential. 
Antimicrobial peptides (AMPs) are alternatives for classic antimicrobial agents as they 
clinically have little side effects, they have rapid activity on their targets, they tend to have 
the membranolytic mode of action as well as other intracellular targets which make 
resistance less likely to occur. Apart from planktonic activities, many AMPs have, 
antibiofilm activity. In this study, we aim to enhance the anti-Candida activity of a group of 
cyclic decapeptides, the tyrocidines, via a formulation with cellulose derivatives, since the 
previous research by our group indicated that tyrocidines have highly potent activity 
against C. albicans. These peptides remain potent after absorption to surfaces which 
makes them the possible solution for creating antimicrobial surfaces in the medical sector. 
Although tyrocidines are haemolytic, it has been previously shown that tyrocidines’ toxicity 
can be lowered in formulations with saccharide derivatives, while the presence of the 
celluloses does not show a significant change on the activity of the peptide. In this project, 
the formulation of tyrocidine mixture and purified tyrocidines and tryptocidines was studied 
in terms of stability and anti-Candida activity. The aims and objectives of this study are 
summarised below. 
 
Aims and objectives 
Aim 1: Produce, purify, and analyse the tyrocidines and analogues. 
In order to reach the first aim, the following objectives were met in this study: 
• Culturing the producer organism Brevibacillus parabrevis ACCT 8185 (Chapter 2). 
• Culturing the high peptide producing cultures in non-supplemented and amino 
acid supplemented media to produce the various tyrocidine analogues (Chapter 2). 




• Purification of tyrocidines and analogues with HPLC and producing pure Trc 
analogues (Chapter 2). 
• Analysing the success of the purification with electrospray mass spectrometry and 
ultra-performance liquid chromatography (Chapter 2). 
 
Aim 2: Formulation and characterisation of the tyrocidine mixture and the purified 
tyrocidines and analogues. 
In order to reach the second aim, the following objectives were met in this study: 
• Formulation of the tyrocidine mixture, tyrocidines and analogues with derivates of 
soluble cellulose such as hydroxypropyl cellulose and hydroxypropyl methyl 
cellulose and chitosan (Chapters 3-5) 
• Assessing the anti-Candida activity of tyrocidines and their cellulose-type 
formulations (Chapters 3) 
• Assessing the haemolytic activity of tyrocidines and their best cellulose-type 
formulations (Chapter 3) 
• Assessing the structure and aggregated form of the peptide in a solution using 
spectrofluorometry (Chapters 4). 
 
An introduction and background to the study is given in Chapter 1 and concluding remarks 
and a discussion on future studies are presented in Chapter 5. The experimental chapters 
in this thesis were written as independent units in article format. This may have led to 
some repetition, but it was attempted to keep repetition to a minimum. 
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Fungi are a diverse group of eukaryotic organisms. To date, around five million fungi 
have been discovered worldwide, with more than 600 pathogenic species 1, 2, 3. Fungal 
infections are a major concern globally. The number of fungal infections is on the rise 
since the 1980s due to the antifungal drug resistance and the expanding population of 
immunocompromised individuals 4. However, the medical sector is not the only sector 
affected by fungal infections, various fungal plant pathogens cause major production 
losses in agricultural, food and beverage industries every year 5, 6. 
Infections caused by pathogenic fungi can be moderate or severe. The moderate 
infections are usually superficial infections which can affect skins and nails of the 
individuals 7. Severe infections can involve different body organs such as kidney, liver, 
and brain 7. They are usually life-threatening, especially in immunocompromised 
individuals with a mortality rate of over 50% 7, 8. The number of fungal infections has 
increased rapidly in the past two decades as the number of immunocompromised 
individuals such as cancer and HIV/AIDS patients, people receiving medical implants 
and elderly people have also increased 9. 
Candida and Aspergillus species are two of the most common causes of fungal 
infections. With C. albicans being the main pathogen responsible for the mucosal 
disease, and Aspergillus fumigatus being mainly responsible for the allergic fungal 
disease which can be extremely dangerous in asthma patients 10. C. albicans 
infections can involve different organs or it can result in a bloodstream infection 11 while 
A. fumigatus primarily involves the lungs by producing airborne spores 10. A. fumigatus 
is largely responsible for the increased incidence of invasive aspergillosis. Non- 
invasive Aspergillus infection normally occurs after repeated exposure to this 
pathogen 3. 
In this chapter, the focus will be on pathogenic fungi, specifically, Candida species as 
we focused the antifungal studies (Chapter 3) of C. albicans as target fungal organism. 
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1.2 Candida infections 
Candida species are the most common cause of human fungal infections. They cause 
a wide range of infections from non-life-threatening illnesses to invasive infection that 
may involve any organ 11. Candida albicans and Candida glabrata are the two major 
fungal pathogens causing more than 50% of Candida infections 12, 13. Antifungal drug 
resistance against a wide range of antifungal drugs has been reported, especially in 
Candida species. It is widely reported that C. albicans and C. glabrata have shown 
less susceptibility to azole and echinocandins families 14, 15, 16, 17, 18, 19. 
Candida species are present in healthy individual’s mucosal oral cavities, 
gastrointestinal tract, and vagina. However, the overgrowth of Candida species can 
lead to various clinical manifestations from mucocutaneous overgrowth to 
bloodstream infections 20. Out of 350 heterogeneous Candida species, more than 17 
different Candida species are responsible for human and animal infections. However, 
the majority of invasive infections are caused by C. albicans, C. glabrata, C. 
parapsilosis, C. tropicalis and C. krusei 21, 22. 
C. albicans is present in the microbiota of 40% to 60% healthy individuals 23. It is often 
found in the gastrointestinal tract, reproductive tract, oral cavities, and skin. 
Although 
C. albicans is often harmless, it can overgrow when there is a change in its host 
immune system or the environment 20, 24, 25, 26, 27. C. albicans’ overgrowth can be 
pathogenic in healthy individuals causing mainly oral and vaginal infection 23. 
However, it is life-threatening in immunocompromised individuals such as HIV and 
cancer patients or during the surgical interventions 28, 29. C. albicans has a great 
tendency to form biofilms. The biofilms usually lead to invasive infection with the 
mortality rate of (36% to 60% depending on the patient immune system) 30, 31, 32, 33. 
Biofilms mainly form on catheters, pacemakers, and implants. Currently, regardless of 
all the advancement in the medical system, C. albicans biofilms on more than 50% of 
the catheters cost $6.25 billion in the United States of America only 34, 35. 
During the course of infection, C. albicans can change its cell shape, alter its cell-wall 
component and secret different types of virulence factors 36. Furthermore, it can 
inactivate defensins, antimicrobial peptides of the innate immune system, and inhibit 
other immune cell functions to weaken the host immune system 36. C. albicans is 
metabolically highly adaptable to environmental changes such as pH, temperature, 
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CO2 level and presence of serum. It can use different nutrition resources and express 
different metabolic pathways. This phenotype flexibility gives it the ability to survive 
the host defence mechanisms 37, 38. 
Although C. albicans is the most common cause of Candida infections, non-Candida 
albicans infections are increasing, especially in immunocompromised individuals 
leading by C. glabrata 39. Based on a study done in the United States of America during 
1989-1999, the number of patients infected by C. glabrata has significantly increased 
while the number of patients infected by C. albicans decreased, therefore it is possible 
that in near future, the incidence of C. glabrata may exceed that of C. albicans 40, 41. 
Furthermore, C. glabrata has the highest mortality rate which is above 60% 42, 43. C. 
glabrata holds few unique features which are unlike other Candida species. As an 
example, C. glabrata is unable of forming pseudohyphae, or it does not cause a high 
neutrophil response from the patience immune system 44. 
 
1.3 Anti-Candida drugs and resistance 
Discovery of antifungal drugs is highly challenging as it is very difficult to find a drug 
that is toxic to fungi but not to human and/or animal eukaryotic cells 45. There are 
currently only four main classes of antifungal drugs, namely, nucleosides 
(pyrimidines), azoles, polyenes and echinocandins 45. Table 1.1 summarises the 
prominent properties of these antifungal agents. Polyenes and azoles target 
ergosterol in the membrane while echinocandins inhibit β1,3 D-glucan in the cell wall 







Table 1.1 Summary of the most well-known examples of current clinical antifungal drugs with reported incidences of resistance by C. albicans 
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* ergosterol is a lipid that is crucial for the maintenance of fungal membrane structure 56 












Figure 1.1 Summary of the mode of action of the main clinical antifungal drugs from each of the four 
drug classes against C. albicans. 
 
Candida resistance development 
Antifungal drugs are generally used at high dosages as treatment failure against fungal 
infections can lead to death 56. Overuse of antifungal drugs and a limited number of existing 
antifungals have caused a rise in antifungal drug resistance 56. There are two main 
categories of resistance namely inherent/primary and acquired resistance 56. Inherent 
resistance describes a phenomenon whereby all known isolates of a species possess an 
innate resistance to an antifungal compound. C. glabrata is a well-known example of a 
species which is inherently resistant to all the drugs in the azole family. The reduced 
susceptibility of C. glabrata to azole family is independent of the presence of acquired 
resistance determinants 44, 57. Acquired resistance occurs in susceptible strains and it 
happens during the therapy. It happens through evolutionary mechanisms that can lower 
the susceptibility of the organism against a given drug. The predominant example of this 
group is the azole resistance in C. albicans 50. Acquired resistance is controlled by internal 
and external factors including environmental pressures, genetic plasticity, and existence of 
hypermutator strain58. The major antifungal drug resistance mechanisms include reduction of 
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drug uptake or biofilm formation. Lower drug uptake can occur via modification of the drug 
target, and/or an upregulation of drug efflux transporters (pumps) which results in the 
reduction in the cellular level of the drug 3. Worryingly, the resistance level across Candida 
isolates is increasing rapidly. There is a significant rise in the numbers of the reported 
resistant isolates of Candida species 59. The mechanisms of resistance development have 
been summarised in Table 1.2. 
The azole family is the first-line treatment of Candida species infections due to its low toxicity 
and oral administration. However, increasing numbers of reported azole resistance is a 
serious concern 60. Azole resistance is usually a stress response. Change in the expression 
of any of the stress-related regulators results in the resistance of the C. albicans species to 
the azole family 61. Candida glabrata is inherently less susceptible to the azole family, 
specifically fluconazole 62. The mechanism of resistance to polyene is close to the 
mechanism of resistance to azole as both of these compounds target the ergosterol in the 
cell membrane 63. Cross-resistance between azole and polyene drug categories is  
common 63. Besides the inherent resistance, C. glabrata develop acquired resistance to the 
azole and polyenes families through different mechanisms of actions 59. Resistance to 
flucytosine is relatively fast and common. This is why flucytosine is usually used with other 
treatments such as amphotericin B 64. Unlike azole resistance, the number of reported C. 
albicans resistance to echinocandins is relatively low but far from rare. Furthermore, prior 
exposure to the echinocandins is significantly linked with resistance 59. Since the beginning 
of widespread echinocandin use, a significant increase in echinocandins resistance 
developed by C. glabrata has been reported. High genetic plasticity of C. glabrata allows for 
easier genomic rearrangement and adoption of the organism to stressful conditions. 
Therefore, the resistance pattern of C. glabrata should be monitored more carefully 44, 65. 
In addition to the explained mechanisms of drug resistance developed by Candida species, 
the formation of biofilms is a major concern in the development of drug resistance. A biofilm 
is a community of cells adhering to each other or on surfaces, possessing properties that 
are different from those of free-floating (planktonic) cells. The major difference between 
biofilms and planktonic cells is the greater resistance of biofilms to drugs 34. Candida species 
have a great tendency of biofilm formation 67. Candida biofilms are organised three- 
dimensional structures consisting of cells in an exopolymeric matrix of proteins, nucleic 






Table 1.2 Summary of mechanisms of resistance developed by C. albicans and C. glabrata towards available clinical antifungal drugs. 
 
 




A. Point mutation in FYC1 and FYC2, encoding cytosine deaminase, inhibits the drug uptake resulting in less accumulation of 
the drug in the cell 
B. Point mutation in FUR1, encoding uracil phosphoribosyltransferase, results in inactivation of uracyl phosphoribosyl 
transferase leading to an alteration in the metabolism of 5-fluorocytosine 59 
azoles 
A. Mutation in Erg11 gene interferes with the inhibition of ergosterol biosynthesis 
B. Mutation in the upregulation of multidrug transporters uptake results in less accumulation of the drug in the cell 66 
 
polyene 
A. Resistance to amphotericin B occurs through mutations in ERG3 which lowers the concentration of ergosterol in the cell 
membrane 
B. Frameshift mutation in ERG2 gens and Point alteration in ERG3 and ERG5 genes decrease ergosterol content in the cell 63 
Echinocandins Mutation in hotspot regions of FKS2 genes reduce the binding affinity of echinocandins 
58, 59 
 





A. Point mutation in FYC1 and FYC2, encoding cytosine deaminase, inhibits the drug uptake resulting in less accumulation of the 
drug in the cell 
B. Point mutation FUR1, encoding uracil phosphoribosyltransferase, results in inactivation of uracyl phosphoribosyl transferase 
leading to an alteration in the metabolism of 5-fluorocytosine 
C. Deletion in FPS1 and FPS2 genes reduced accumulation of the drug 65 
 
azoles 
A. Absence of calcium signalling (essential for azole treatment) results in the inherent resistance 63 
B. point mutation in PDR1 transcription factor resulting in the upregulation of drug efflux pump 59 
 
polyenes 
A. Resistance to amphotericin B is developed through point mutations in ERG2 and ERG6 genes which lowers the concentration 
of ergosterol in the cell membrane 
B. Point alteration in ERG2 and ERG6decrease ergosterol content in cells 59 
Echinocandins 
A. Mutation in hotspot regions of FKS1 genes reduce the binding affinity of Echinocandins 











The greater tendency of the development of resistance by Candida biofilms is due to 
different factors such as alterations in efflux pump expression, changes in the cell membrane 
and wall composition and the presence of persister cells. Furthermore, the glucan matrix 
surrounding the biofilm physically prevents antifungal compounds from reaching cells 69. 
Fungi are extremely adaptive against cellular stress which usually leads to elevated 
minimum inhibitory concentration of antifungal compounds. The exposure of the cells to 
antifungal compounds causes cell stress. As a response to drug-induced stress, stress 
regulator factors such as Hsp90 and calcineurin would be expressed. The expression of the 
cellular regulators led to the formation of biofilms or acquired resistance 70. The drug 
resistance developed by Candida species is directly related to previous exposure especially 
in the presence of azole and echinocandins 61, 56. The lack of proper treatment for Candida 
infections and the emergence of resistance intensifies the need for the development of new 
anti-Candida drugs. 
 
1.4 Antimicrobial peptides as candidate antifungal drugs 
Antimicrobial peptides (AMPs) are the novel generation of antimicrobial agents. Due to their 
rapid eradication of the target organism and different mode of actions, resistance is less 
likely to occur against them 71, 72. Within the large family of AMPs, there are peptides with 
the ability for antifungal activity, including tyrocidines (Trcs) and analogues, which are the 
focus AMP in this project 73, 74, 75. 
AMPs are relatively small gene-encoded molecules, comprising 12 to 50 amino acids, which 
can be found in all prokaryotic and eukaryotic organisms 76. AMPs are usually the first line 
of defensive mechanisms in their hosts 77, 78. Examples of antimicrobial peptides include 
nisin isolated from bacteria 79, plectasin from fungi 80, cecropins from insect 81, 82 and 
defensins from plants and humans 83, 84. 
Although AMPs share many similarities, they have distinct structural differences. 
According to a review by Epand and Vogel 85, AMPs are categorised into four categories 
based on their structures. These categories include α-helical AMPs, β-sheet AMPs, 
AMPs with unusual amino acids and AMPs consisting of the thio-ether ring. AMPs with 
alpha-helical structures are mostly cationic and amphipathic such as magainin 86, 87, 88. 
However, there are AMPs with α-helical structure that are either anionic such as alamethicin 
89 or hydrophobic such as gramicidin A 90. AMPs that have β-sheet structures are mostly 
cyclic with disulphide bonds such as certain defensins 91 or N-C cyclisation such as 
gramicidin S and tyrocidines 92, 93. Tritrpticin, which is rich in tryptophan, is a typical example 
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of AMPs with unusual amino acids sequences 94. The last group belongs to lantibiotics 
which are bacteriocin with a cyclic structure and a thio-ether ring such as nisin 95. 
AMPs are potential alternatives to classical antimicrobial agents as resistance is less likely 
to occur against them due to their rapid and multiple modes of action 96. AMP mode of action 
can be generally classified into two main groups, namely membrane disruptive and 
membrane non-disruptive 73. Different theories explain how membrane disruptive AMPs can 
bind to their target and eradicate them. One such a theory is the Barrel-Stave model 97, 98 
which states that peptides undergo horizontal orientation in a way that the hydrophobic part 
of the peptide can face towards the hydrophobic part of the membrane and hydrophilic part 
face towards the inside. This orientation leads to the formation of pores that can result in 
leakage of the cell components 97, 98. Another theory that explains the mechanism of action 
of membrane-disruptive mode of actions is called the toroidal pore model 99 which explains 
that AMPs can bind to the membrane and force the lipid to fold inwards and form channels 
which can lead to the cell leakage 98, 100, 101. The carpet model 102 is the third theory which 
believes in the association of AMPs with the membrane and destruction of the 
electrostatics of the cytoplasmic membrane which leads to the collapse of the membrane 
into a micelle and consequently the cell death 98. Examples of the non-membrane 
disruptive mode of action include interference with RNA or DNA synthesis, enzyme 
functions and, the process of cell division 103, 104, 105,106, 107, 108. AMPs’ mode of action is 
highly dependent on the target’s cell membrane organisation and the peptide structure. For 
instance, the bacterial membrane is a good target for cationic peptide as they mostly 
contain phospholipids and a negatively charged membrane while eukaryotic cells are 
normally neutral in charge which leads to a low affinity of peptide 109. 
1.4.1 Antifungal peptides 
Antimicrobial peptides with antifungal activity (AFPs) have emerged as good candidates for 
novel antifungal drugs due to their efficacy and lower chance of resistance development. 
Although AFPs cause fewer side effects compared to classic antifungal agents, the majority 
of AFPs have cytotoxic properties 110. Unlike, AMPs with antibacterial properties, little is 
known about AFPs which makes their classification challenging. In this review, AFPs are 
categorised into two categories based on the mode of action and origin. In each of the 
categories, a few examples with anti-Candida activity will be mentioned. Antifungal peptides 
Stellenbosch University https://scholar.sun.ac.za
1-11  
can be isolated from natural, semisynthetic, or synthetic sources 111. For the purpose of this 
review, a few examples of each category with anti-Candida activity are given in Table 1.3. 
Antifungal peptides with primarily antifungal activity 
 
The majority of AFPs have a broad spectrum of activity with few peptides having primarily 
or exclusively antifungal activity 112 such as echinocandins, nikkomycins and aureobasidins, 
defensins and histatins. Echinocandins are a family of cyclic lipopeptides inhibiting glucan 
synthesis. Echinocandins non-competitively inhibits the enzyme 1,3-β-glucan synthase 
resulting in destabilisation of the cell wall 113. Nikkomycins and aureobasidins inhibit the 
chitin in the cell wall. Chitin is a cell wall component crucial for the maintenance of the 
structural integrity of the fungus, which is absent in all vertebrates 114, 115, 116. These peptides 
show significant anti-Candida activity while they are not toxic to human cells 117. Plant 
defensins such as HsAFP1 and DmAMP1 118, as well as insect defensins 119, are membrane- 
active AFPs with proven anti-Candida activity 118. Histatins are histidine-rich peptides with 
membrane activity and/or intracellular target 120, 121, Furthermore, histatins have strong anti- 
Candida activity 122, 123. 
Antifungal peptides with a wide spectrum of antimicrobial activity 
 
Most AMPs are also AFPs and have a broad spectrum of activity affecting bacteria, fungi, or 
viruses. Most of these peptides have a membranolytic activity which is usually toxic to 
mammalian cells at higher concentration 112. These peptides are broadly categorised in two 
groups of linear and cyclic peptides 124. Linear peptides include cecropins 125, magainins 88, 
and dermaseptins 126 and are small with an amphipathic α-helical structure. They primarily 
disrupt the membrane but some of them have unique intracellular targets 127, 106. Although 
cyclic and linear peptides mainly target the membrane, most of them have their unique mode 
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1.5 The tyrocidines as potential AFPs 
Tyrocidines (Trcs) and analogues are broad-spectrum AMPs with promising anti-Candida 
activity 75, 76. Trcs and analogues are extracted from the tyrothricin complex, which is 
non-ribosomally produced by Brevibacillus parabrevis 141, 142. Tyrothricin is a classic 
antibiotic that was discovered 10 years after penicillin 141. The remarkable anti-Candida 
potency of Trcs and the fact that there has been no resistant reported to date make Trcs 
potential candidates for the treatment of Candida infections 75. 
Tyrocidines (Trcs) are small cyclodecapeptides, sharing the Val-Orn-Leu-D-Phe-Pro 
pentapeptide sequence with the well-known peptide, gramicidin S 143, 144. Figure 1.2. shows 
the primary structure of gramicidin S (GS), tyrocidine A (TrcA) and tyrocidine C (TrcC). 
 
 
Figure 1.2 Primary structures of analogous cyclodecapeptides TrcA, TrcC and GS. The three 
peptides share the conserved VOLfP pentapeptide moiety in their cyclic structure. Standard three 
letter amino acid abbreviations are used in the annotation except Orn representing ornithine. The 
residue numbering is according to the order of biological synthesis. 
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The cyclodecapeptides from tyrothricin have a fairly conserved sequence, cyclo (D-Phe1- 
Pro2-X3-x4-Asn5-Gln6-X7-Val8-X9-Leu10) (Figure 1.2). The X3/x4 indicates the variable L- or D- 
aromatic amino acid residues respectively, with Phe3-D-Phe4 to give the A analogue 
peptides, such as TrcA, Trp3-D-Phe4 in the B group such as tyrocidine B (TrcB), Phe3-D-
Trp4 in the B’ group and Trp3-D-Trp4 in the C group such as TrcC (Figure 1.2). The 
tyrocidines (Trcs) have a Tyr at position 7, while the tryptocidines (Tpcs) have a Trp7 and 
the phenycidines (Phcs) a Phe7. All these peptides can have either ornithine (Orn) or Lys 
in position 9 as cationic residue. 144. Those with Lys9 is denoted with a subscript 1 after the 
group for example TrcA1 and TrcC1. The variation at the non-conserved positions 
accounts for the presence of 24 different analogues of Trcs, which was characterised by 
Tang et al. 144. However, Leu or Ile can be substituted at position 8 which can give rise to 
a possible 72 minor analogues 144. Substitutions of Ile/Leu/Tyr in positions 3 or 4 bring 
the total to about 450 possible cyclodecapeptide peptides in tyrothricin. 
The cyclodecapeptides (Trcs and analogues) constitute 50-60 % and linear gramicidins 10- 
20% of the peptide mass that are produced as the main components of tyrothricin complex 
144 during the late logarithmic growth phase of Brevibacillus parabrevis 141, 142. The benefits 
for Brevibacillus parabrevis that is offered by the production of the tyrothricin complex are 
not clear, but it is assumed that the antimicrobial activity of tyrothricin towards other 
organisms provides a competitive advantage for the producer organism. Furthermore, 
production of tyrothricin complex might play a role in the sporulation 145. 
The production of cyclodecapeptides and gramicidins in tyrothricin is non-ribosomal and 
encoded by the tyrocidine and gramicidin biosynthesis operons 146. The thio-templated non- 
ribosomal peptide synthesis is achieved through multi-domain enzyme complexes 
containing non-ribosomal peptide synthetases (NRPSs) 146, 147. In the Trc production 
process, there must be of amino acids available within the growth medium for a sequential 
addition into the cyclodecapeptide structure by the NRPSs 142, 147. This process takes place 
during the late logarithmic growth phase under oxygen limiting conditions 148. The media of 
the producer organism must contain nitrogen resources such as urea and carbon 149, 150. 
The production of Trcs and its analogues can be manipulated via amino acid 
supplementation of culture medium. Addition of Trp will shift the production towards the Trp- 
rich Tpcs while the addition of Phe shifts the production towards the Phe-rich Phcs 151. 
TrcA in the tyrothricin complex is one of the first peptides of which the structure was 
elucidated. It has a secondary structure consisting of an antiparallel β-sheet between 
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Trp/Phe3-Asn5 and Val8- Leu10 that is linked by a type I (Gln6-Tyr7) and type II (D-Phe1-Pro2) β-turn 152 (Figure 
1.3). One study indicated that the hydrophobic interaction between some of the side chains of TrcA leads 
to a curved structure and dimerisation which is responsible for its amphipathic characteristics 153. 
 
 
Figure 1.3 The 3D structure of TrcA (top) and an amphipathic dimer of TrcA (bottom). TrcA stick 
structures are shown on the left and the corresponding ribbon structures with aromatic residues on 
the right. Carbon is shown in turquoise, nitrogen in blue and oxygen in red. Hydrogens were omitted 
from the structure. The dotted yellow line indicated hydrogen bonds, the red arrows antiparallel - 
sheet, green and turquoise tube -turns. The images are courtesy of V. Kumar and M. Rautenbach 
and were modelled utilising Yasara 11.3.2. The original 3D models used to create the 3-D structures 
were based on models by Munyuki et al. 93. 
A second study showed that TrcA and TrcC can form various dimeric structures with 
amphipathic properties 93. The amphipathic structure of these cyclodecapeptide dimers 
(Figure 1.3) is important for the association with the negatively charged bacterial/fungal cell 
membrane which leads to the destabilisation of the membrane and, therefore, death of the 
cell 93, 152. Furthermore, it could be that the β-sheet structure of such cyclodecapeptides 
154,155, 156 allows them to maintain its stability under different environmental conditions such 
as a range of temperatures or solvent. The Trcs also maintain its antifungal activity in the 
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presence of Mg2+, K+ and Na+ 156. Ca2+ has a negative effect on the antifungal activity of 
these peptides 157 but increases their anti-listerial activity 129. 
The activity of the Trcs and analogues is dependent on three main factors including the 
target organism, mode of action, structure, and resultant oligomerisation. This group of 
cyclodecapeptides have a broad spectrum of antimicrobial activity against parasites 
(Plasmodium falciparum 159, 160, 161), Gram-positive bacteria (Diplococcus pneumoniae, 
Listeria monocytogenes 161, 162) and fungi such as Candida albicans 75, Neurospora crassa 
163 and filamentous fungi 158, 164. However, previous studies on Escherichia coli, indicated that 
Trcs are not very active against Gram-negative bacteria 163. In addition to the 
antimicrobial activity, Trcs possess toxicity properties against mammalian cells 165, 166, 167. 
Trcs are haemolytic and leukocytolytic 166, however, they are relatively safe when used 
topically or orally 167. 
The Trc antimicrobial and haemolytic activity occur very rapidly. Trcs show their 
antimicrobial activity within two to four seconds 161, 167. Moreover, Trcs do not maintain their 
full antimicrobial activity in the presence of blood serum therefore it is suggested to use the 
Trcs in the direct contact with the target organism 170. Although there is still no complete 
model for tyrocidines mode of action, Trcs’ main target has been identified as the microbial 
membrane, with some studies indicating membrane proteins as targets and unknown 
intracellular targets 129, 156, 162. Early studies suggested Trcs have intracellular targets such 
as DNA in the producer organism resulting in inhibition of some NADH enzymes 170 and the 
food vacuole or cell cycle regulators in the human malaria parasite 157, 165. 
Trc antimicrobial activity has been largely attributed to their membrane lytic mode of actions 
which is initiated by a series of hydrophobic and ionic interactions as well as hydrogen 
binding 129. Trcs oligomers have been proposed to form channels or pores throughout the 
bacterial membrane resulting in the cell lysis 162, 167. In a study done by Wenzel et al. 143, the 
mode of action of TrcA and TrcC has been investigated in more detail and compared with 
that of gramicidin S (GS) which share more than 50% similarity on the sequence identity 
with Trcs. This study suggested that the difference between the antibacterial activity of Trcs 
and GS is due to the presence of four aromatic amino acid residues on the Trcs and two Phe 
in GS. Furthermore, Trcs have the ability to form dimers 93,152 while there has been no 
evidence to date that GS forms dimers. This study illustrated that Trcs are able to form pores 
through the membrane, but the exact mechanism of pore-forming ability of Trcs is not clear. 
Both Trcs and GS target membrane by affecting membrane fluidity. Wenzel et al. 143, as 
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showed that TrcA and TrcC target membrane proteins as well as DNA. In fungi, Trcs also 
may have both membranolytic activity and intracellular targets 171,172. Troskie et al. 159 
showed that the removal of the fungal cell walls significantly influenced the Trc activity. 
Rautenbach et al.110 showed that these peptides have a rapid membranolytic activity that is 
influenced by ergosterol, glucosylceramides and the fluidity of the phospholipids in the 
fungal membrane. 
 
1.5.5 Trc oligomerisation, toxicity, and structure-activity relationships 
Trcs have a strong tendency to oligomerise 152, 173. Interestingly, the antimicrobial activity of 
Trcs may be dependent on their ability to form oligomers. One of the first studies done 
by Ruttenberg et al. 173 showed that the lack of oligomerisation results in loss of 
biological activity. However, another early study showed extensive oligomerisation of Trcs 
results in loss of activity 174. Therefore, there could be a critical point of oligomerisation which 
results in the maximum antimicrobial activity of the Trcs 174 and manipulation of Trcs 
oligomerisation profile can potentially result in a change in their biological activity. It is 
hypothesised that Trcs dimers are responsible for the antimicrobial activity of Trcs. Based 
on a model designed by Loll et al. 152 Trcs can form arrow-shaped dimers that interact with 
membranes. 
Based on the study done by Troskie and Rautenbach 76, TrcA is the most active analogue 
of Trcs against C. albicans while phenycidine A (PhcA) with a Phe7 rather than a Tyr7 was 
the least active analogue. The aromatic residue differences in the cyclodecapeptide primary 
structure led to differences in hydrophobicity, while the different Mr led to a difference in m/z 
ratio, as well as overall surface and volume of the peptide 93, 144. This can cause minor 
conformational differences of the peptide which could change the oligomerisation, as well 
as affinity or type of the interaction with the target cell and result in the change in the activity 
of the peptide 93, 152. 
Manipulation of the structure of most AMPs results in a change of their antimicrobial and 
haemolytic activity. As an example, introduction of positively charged residues to the 
analogous GS has increased the biological activity while decreasing the haemolytic activity 
175, 176, 177. According to Kohli and Wash 178, the antimicrobial activity of Trcs has been 
correlated to D-Phe4 and Gln6 residues within the Trc amino acid sequence. Substitution of 
D-Phe4 that can insert into the hydrophobic bilayer, with basic D-amino acids, Orn, Arg or 
Lys, led to a more cationic peptide and significantly improved the biological activity and 
selectivity 178. Substitution of the D-Phe4 residue by negatively charged D-Glu or D-Asp led 
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to a loss of antibacterial activity 177. The enhanced activity of Trc upon increasing positive 
charge might be attributed to the better ability of the Trc to interact with the negatively 
charged phospholipid bilayer. The previous study on synthetic TrcA by Marques et al. 179 
showed that manipulation of Trc A structure leads to a change in the antibacterial activity of 
the peptide against E. coli. This group attempted to find the relationship between the overall 
amphipathic character and the biological activity of TrcA. With solid-phase synthetic 
methodology, they synthesised TrcA and eight different analogues. These analogues were 
achieved via point substitution that would affect either the polar or nonpolar face of the 
molecule. The result showed that there was an increase in antibacterial activity when the 
amphipathicity of TrcA was increased 179. Furthermore, amino acid substitution can alter the 
oligomerisation profile that can result in the change of the activity 176, 178. As observed for 
GS, cyclic conformation is also important for the antibacterial activity of the tyrocidines 176. 
In short, the activity and selectivity of Trcs are dependent on the balance of amphipathicity 
and positive net charge 172. Therefore, change in the amphipathicity, hydrophobicity or 
general structure of the peptide results in a change in the haemolytic or antimicrobial activity 
of the Trcs. 
Although structural modification of Trcs showed enhanced biological activity and lower 
toxicity, this complicated synthetic process, as well as the high cost, do not favour utilisation 
of this method for large scale production. Alternatively, drug combinations could lower the 
amount needed and therefore result in lower toxicity. Troskie et al. 75 attenuated the TrcA 
anti-Candida activity via combination with an antifungal drug. In this study, the lower TrcA 
concentrations needed for activity reduced the toxicity when synergistic mixtures of 
TrcA+caspofungin and TrcA+amphotericin B was used to obtain potent anti- Candida activity. 
Furthermore, peptide formulation could be more of cost and time effective. If a suitable 
formulation for the Trcs can be found, specifically a formulation that can increase the 
peptide stability, oligomerisation, and selectivity, it can yield better preparations for topical 
and oral administration. It could also be combined with synergistic antifungal drugs for last 
resort systemic applications. 
 
1.5.6 Formulation of anti-fungal drugs 
Formulation or covalent modifications of the peptides are used for various reasons, namely, 
the Improvement of the peptide’s biological activity 179, 180, broadening the antimicrobial 
activity 181, lowering the toxicity 182, improvement of solubility (especially in an aqueous 
environment) 183, 184, improvement of stability and increasing the drug shelf life 185. In some 
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cases, the formulations or modifications are used to overcome the antimicrobial resistance 
186 or it is used as a targeted delivery system for the drug of interest 187. This delivery system 
can protect the drug from the hosts' enzymes, especially when the drug is consumed  
orally 188, or it can lead to the controlled release of the drug 189. 
 
The most successful formulations for many drugs, including peptides entail the use of 
different types of lipids (including lipid-type detergents) and saccharides. A brief overview of 
these two types of formulants will be given. 
Lipid formulations 
 
Lipid-based drug delivery systems, by encapsulating or solubilising the drug of interest in a 
lipid formulant, are became more prevalent in drug formulations in the past few decades. 
Lipid formulations can the done through multiple approaches, such as, solubilising a 
lipophilic drug in an oily solution 190, or through the formation of mixed micelles and 
liposomes, or even by using a solid lipid nanoparticle 191. In a system that consists of more 
than one compound with differing hydrophobicity, the formulation can occur through the 
formation of mixed micelles. In detergent-lipid mixed micelles, the detergent molecules 
enhance the emulsification of the lipid of hydrophobic molecules to ensure better aqueous 
compatibility 191. Formulation through the formation of liposomes is done by using 
phospholipids to form the vesicles and encapsulate the drug 192. Phospholipids are 
amphiphilic as the fatty acyl chains form the hydrophobic tail groups and the phosphate form 
the head group. As the consequence of this property, they can form bilayer structures such 
as vesicles or liposomes with the hydrophobic tails facing each other and the polar head 
group on the surface and on the inside of the bilayer structure 192. The advantage of this 
system is that both hydrophobic and hydrophilic drugs can be formulated. Lipid nanoparticles 
are typically spherical nanoparticles with both liposomal and micellular character and can be 
used to solubilise lipophilic drugs for systemic applications 191. 
In lipid formulations, the drug is encapsulated by lipid therefore, when the drug is consumed 
orally, it will not get degraded by the gastrointestinal tract enzymes. After the absorption of 
the lipid-drug formulation by the enterocytes, possibly via the chylomicron system, the lipid 
capsule will slowly degrade to release the drug 193. For nasal administration, this could lead 
to slower and more controlled release in the nasal passages, as well as protect the drug 
from the host and pathogen enzymes 187, 188, 194. Lipid formulations can also be used for 
systemic application via direct infusion into the bloodstream 190, 191, 195. Also, the immune 
response, as well as the toxicity of most drugs are decreased in lipid formulations 195, 196. 
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A well-known example of a successful lipid formulation of a peptide is the lipid formulation 
used for the drug cyclosporin A. Cyclosporin A is a non-ribosomally synthesised peptide with 
weak antimicrobial activity 197, which is mainly used for arthritis treatment 197. Due to the side 
effects of this peptide such as neurotoxicity, cytotoxicity hepatotoxicity, and nephrotoxicity, 
long term treatment is extremely limited. However, cyclosporin A formulated by a polymeric 
Micelle (methoxy poly (ethylene glycol)-hexyl substituted poly (lactide)) and surfactants 
(Cremophor EL) shows significantly lower toxicity and improved stability 197. An example of 
a lipid formulation that improved the activity of an AMP is that of gramicidin A, a non- 
ribosomal AMP that is found in the well-known tyrothricin complex 90, 182. Gramicidin A 
formulated by cationic bilayer fragments forming disc-like structures shows a broader 
biological activity towards both Gram-positive and Gram-negative bacteria 182. These lipid 
bilayer discs were prepared by sonication of charged lipids or by using liposome  
fragments 182. 
Another benefit of lipid-formulation is that lipid formulation can protect AMPs from host 
enzymes. A study showed that lipid-formulation of the AMP, α-helical CM3, protected the 
peptide from peptidases when it was inhaled 194. Liposomes encapsulate α-helical CM3 
successfully delivered via an inhaler to the lungs of the rats infected by P. aeruginosa. This 
formulation also reduced the toxicity of the peptide, combined with protecting the peptide 
against proteolytic degradation 194. 
Amphotericin B (AmB) is a well-known antifungal drug, with similar membranolytic and 
haemolytic activity than the Trcs 198, 199, 200. AmB is one of the most reliable anti-fungal 
treatments and a last-resort drug 197. AmB has been successfully formulated with lipids to 
limit is toxicity and allow systemic application 199 as it is not only haemolytic, but it has other 
toxicities such as nephrotoxicity 45, 199. Therefore, to reduce the toxicity, different lipid- 
formulations have been developed. The lipid formulations of AmB not only results in less 
toxicity but also protects the drug from enzymatic degradation and the host immune system. 
The liposomal formulation of AmB (L-AmB), marketed as AmbisoneTM is used for a 
controlled drug release 194, 195, 196. A slow release of AmB results in the diversion of the drug 
from the kidney. The other lipid formulation of AmB includes AmB lipid complex (ABLC) 
marketed as Abelcet TM, and AmB colloidal dispersion (ABCD) marketed as Amphocil™ and 
Amphotec TM 195, 196, 201, 202. Pure lipids are not the only formulant for hydrophobic drugs, 
such as AmB. As an example, AmB is formulated by a bile-salt (steroid-type detergent) 
called sodium deoxycholate, marketed as FungizoneTM that increased the AmB solubility in 
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saline, as well as lowered its toxicity 201. This detergent formulation of AmB results in the 




Novel saccharide based formulants are predicted to be the next breakthrough in drug 
discovery due to the high molecular weight and the strong interaction with the drug 
molecule and low manufacturing costs 197. The formulation of drugs via saccharides can 
occur through different approaches such as solubilisation, nanoparticles 203 or Dextran- 
based gel-coupled drugs 204, 205. 
Cyclodextrins (CDs) are the most well-known saccharide group used in drug formulation. 
CDs are cyclic oligosaccharides that are produced by enzymatic degradation of starch 206. 
These molecules have a doughnut-shaped structure with a hydrophilic outer surface and a 
relatively hydrophobic inner cavity. The hydrophobic drug molecules can be entrapped by 
the hydrophobic inner cavity of the CDs 206. A wide range of molecules especially peptides 
and proteins can interact with the CDs hydrophobic inner cavity. The main forces of the 
interaction between the CD’s cavity and drug molecules include van der Waal forces, 
hydrophobic bonding and hydrogen bonding 207. However, CDs complex formation is a 
dynamic equilibrium in which one drug molecule continuously associates and dissociates 
with one CD molecule 207. Furthermore, CDs can form water-soluble inclusion complexes 
with poorly soluble compounds 207. By substitution of different functional moieties such as 
methyl (CH3), hydroxypropyl (CH2‐CHOH), and sulpho-butylether ((CH2)4‐SO3Na) with the 
CD’s hydroxyl groups, different CD derivatives can be obtained 208. CD-containing 
formulations have been extensively used for drug delivery and controlled drug release 209,210, 
211 enhancing drug permeation 212, increasing drug solubility and stability 213. Furthermore, 
CDs formulation have shown to reduce several drugs toxicity 214. However, the toxicity of 
the CDs alone depends on the administration route. As an example, natural CDs and their 
derivatives are well tolerated when consumed orally and they are listed as an inactive 
ingredient by the FDA 214. Formation of self-assembly structures of CD-drug complexes can 
lead to innovative drug delivery system, as an example; water-soluble or water-insoluble 
drugs can be loaded on the hydrophobic or hydrophilic parts of CDs, while CDs act as 
nanocarriers for drug delivery. CDs can be structurally tailored to form different 
nanostructures such as nanospheres, nanomicelles and nanoparticles 216. The most 
common application of CDs as formulant is to increase the solubility of less soluble drugs in 
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water. To formulate the poorly-water-soluble drugs, the drug must have a lipophilic moiety 
capable of entering the hydrophobic CD cavity 216. 
Chitosan is a naturally occurring saccharide and it is considered as a non-toxic polymer for 
oral admiration in many countries such as Japan and Italy 217. Chitosan is found in a variety of 
molecular weight 218, size and deacetylation forms 219. Chitosan has a concentration-
based viscosity in which the viscosity increases as the concentration increases 220. 
These characteristics make chitosan an easy polymer for further modification and 
therefore, a suitable saccharide for the drug formulation. Exendin-4 is an example of a 
peptide, although it is not an AMP, that was successfully formulated in chitosan nanoparticles 
221. This peptide promotes insulin synthesis and secretion 222. It also inhibits the apoptosis of 
pancreatic β- cells, leading to the reversion of diabetes type II 222. Formulated exendin-4 
as inhalable nanoparticles that was composed of glycol chitosan showed an enhanced 
therapeutic effect on diabetes type II 219. 
Cellulose derivatives are also ideal for drug formulations, as they are cheap and 
biodegradable and non-toxic 223. Cellulose is the main structural component of plant  
cells 223. It is a polysaccharide consisting of linear chains of 1-4-linked β-D-glucopyranose 
units 223. Cellulose molecules can have different polymer chain lengths, but they mainly 
have a high molecular weight, are insoluble and mostly contain 1-4-linked glycosidic bonds 
which makes it non-digestible in the gastro-intestinal tract 224. This stability makes cellulose-
type formulants good candidates for drug formulation 225, 226. Natural celluloses with shorter 
chain lengths are only weakly water-soluble 225, 226. However, partial hydrolysis and the 
etherification of hydroxyl groups give rise to new cellulose derivatives with significantly better 
water-solubility 225, 226. Ether-cellulose derivates include methylcellulose, (MC), 
ethylcellulose (EC), hydroxypropylcellulose (HPC), hydroxyethylcellulose (HEC), and 
hydroxypropyl methylcellulose (HPMC) 225. As the interest of this project focused on HPC 
and HPMC, they will be briefly discussed. HPMCs are non-ionic, hydrophilic, and soluble in 
water, methanol, ethanol, propanol, and dichloromethane. Their solubility in most organic 
solvent makes them a perfect candidate for formulation while their water solubility eases the 
formulation preparation as the freeze-drying technique can be utilised during the  
preparation 225, 226. They are often used as formulant for stabilising agent or to increase 
drug solubility 225. In a study done by Jung and Yoo 227, the anti-fungal drug. itraconazole, 
was successfully formulated by HPMC, using solid dispersion techniques. This formulation 
exhibited increased water solubility while maintaining the activity. In another study done by 
Terreni et al. 228 a synthetic AMP called hLF 1-11, which is a peptide utilise in curing 
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infectious ocular keratitis was formulated by HPMC in an attempt to increase the drug 
stability and shelf- life. The result was extremely promising as the activity of the peptide was 
maintained while the stability increased 228. 
In this study, we will be focusing on cellulose type formulations of the Trcs to increase the 
stability of the peptides in solution, lower the toxicity and maintain or increase the activity 
against the pathogen. C. albicans. We will first report the preparation of the Trcs in Chapter 
2 and track the activity and stability in Chapter 3 and 4. The overall conclusion on the 
success and failures of the cellulose-type formulations will be given in Chapter 5. 
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Production, purification, and chemical characterisation 
of the cyclodecapeptides from tyrothricin 
 
2.1 Introduction 
Antimicrobial peptides are potential alternatives for the classic antifungal drugs as 
resistance is less likely to occur against them due to their multiple modes of action 1. 
Tyrocidines (Trcs) are one of the first group of antimicrobial peptides discovered by 
Dubos in 1939 2, 3. They show a wide range of antimicrobial activity to different targets 
including, human malaria parasite, (Plasmodium falciparum) 4, Gram-positive bacteria 
5, and various pathogenic fungi 6, 7, 8. For this study, the antifungal activities against 
Candida albicans 8 motivated us to investigate this group of peptides further. 
The Trcs are relatively small cyclic peptides with a conserved sequence of 10 amino 
acids, with a general conserved sequence as cyclo (D-Phe1-Pro2-X3-x4-Asn5-Gln6-X7- 
Val8-X9-Leu10). The X/x indicates the variable L- or D- amino acid residues respectively, 
namely Trp or Phe at residue positions 3 and 4, Trp, Phe, or Tyr at position 7, and the 
cationic residues ornithine (Orn) or Lys at position 9 9. Table 2.1 summarises different 
Trc analogues that are generally found in tyrothricin extracts from cultures of the 
producer organism Brevibacillus parabrevis (B. parabrevis) 10. 
This study aimed to enhance the anti-Candida activity of Trcs via cellulose derivatives 
formulation, in addition to, characterisation of formulated Trcs via biophysical studies. 
To investigate the biophysical characteristics and biological activity of the Trcs, purities 
of 90% or higher is required, as with a low purity of peptide, other compounds might 
influence the peptide’s biological activity or biophysical characteristics. A multi-step 
organic solvent extraction method, already established within the BIOPEP Peptide 
Group was used to separate the cationic cyclo-decapeptides (Trcs) from the non-polar 
linear gramicidins (Grms) present in sample 11. To achieve high purity of Trcs, an 
optimised method of reversed-phase high- performance liquid chromatography (RP-




Table 2.1 Summary of the cyclodecapeptides generally found in tyrothricin extract from Br. 















Phenycidine Ac PhcA 
Cyclo- 
(fPFfNQFVOL) 
1253.6597 1254.6675 627.8377 
Phenycidine A1c PhcA1 
Cyclo- 
(fPFfNQFVKL) 
1267.6753 1268.6832 634.8455 
Tyrocidines 





































































































































a Standard one letter amino acid abbreviations used in peptide sequences, O representing Ornithine and lower- 
case letters representing the D-amino acids. 
b Theoretical monoisotopic relative molar mass (Mr) calculated as the sum of the monoisotopic Mr values of 
amino acid residues in each peptide. c Low amounts detected. 
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As RP-HPLC involves the separation of molecules based on their hydrophobicity, the 
stationary phase contains hydrocarbons such as C4, C8 and C18 13, 14. In this study, C18 
HPLC matrix was utilised as longer chain carbons are more appropriate for the 
separation of peptides due to their amphipathicity. The mobile phases in RP-HPLC of 
peptides generally comprises of a polar solvent such as water that is followed by a 
more non-polar organic solvent such as acetonitrile 13, 14. Trifluoroacetic acid (TFA, 0.1-
0.5% v/v) is frequently used as solvent modifier for peptide separation 13. In the 
separation amphipathic peptides interact with the C18 chain. The organic solvent in the 
flowing mobile phase utilising a gradient will compete with the C18 interactions and the 
peptides will elute based on their hydrophobicity 14. Peptides with weaker hydrophobic 
interaction (more polar peptides) will elute first while peptides with stronger 
hydrophobic interaction (more hydrophobic peptides) will be retained on the column 
longer until the hydrophobicity of the mobile phase is sufficient for them to elute. In this 
study 1%, trifluoroacetic acid was included in the mobile phase as this acid is a 
counter ion to the peptide, the peptides and the acid can form an ion pair with sufficient 
hydrophobic properties 13, 14, 15. It is also proposed that TFA decorates the peptide 
backbone presenting the Fluor-group leading to a more hydrophobic complex 13. 
Resolution during reversed-phase HPLC chromatography is highly dependent on the 
composition of the mobile phase, small changes such as variation in temperature or 
the flowrate can affect the separation and resolution 13, 14, 15. Therefore in this study, 
chromatography was done at a constant temperature of 35°C, a constant flow rate of 
3mL/min and a strict timed gradient program that allowed peptide association, the best 
resolution possible and column regeneration and equilibration. The purified fractions 
of the peptide analogues were then analysed using reverse phase ultra-performance 
liquid chromatography linked to high resolution electrospray mass spectrometry, 
(UPLC-ESMS) to confirm the identity and integrity of the peptides and determine the 
purity, present within the sample. 
The peptides present within the B. parabrevis extract presents a wide range of 
molecular masses, with peptides differing from one another by only one or two different 
amino acid residues. The peptides also tend to form dimers and associate with sodium 
and potassium leading to overlapping molecular masses. Mass spectrometry, in 
particular, high resolution electrospray mass spectrometry (ESMS) is the ideal method
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for the analysis of such complex peptide mixtures and has become extremely popular 
for the structural investigation for peptides mixture or highly pure peptides, because of 
the high accuracy of this technique (<5 ppm error on Mr of a compound) 16. A mass 
spectrometer consists of three main components: an ionisation source that is 
responsible for the ionisation of molecules, a mass analyser for maintenance of the 
electric field and separation of molecules based on their mass over charge (m/z) ratio 
and a detector such as a photomultiplier which is responsible for detection and 
conversion of ions to an electronic signal, all of which are maintained under an 
extremely high vacuum 16. 
The ionisation source utilised in this study was an electrospray ionisation (ESI) source. 
ESI is a popular ionisation method specifically for proteins and peptides. ESI is an 
evaporation-based ionisation mode which involves the production of the fine spray of 
charged liquid droplets using a high voltage. Thereafter, high vacuum and high 
temperature (i.e., 275 °C) are applied to the highly charged sample droplets which 
result in the evaporation of the solvent and release solvent-free ions in the gas phase 
into the analyser. This method of “soft” ionisation is capable of generating singly 
charged and multiple charged ions. On average one charge is added for every KDa of 
the mass of the protein sample 17. 
If we pass the gas phase ions of complex peptide mixture through a powerful magnetic 
field in the mass analyser, the different peptides will be deflected differently by the m/z, 
if all molecules present within the mixture carries the same charge, the separation 
would be only based on their mass 18. There are various types of mass analysers, but 
the analyser used for this study is called the quadrable time of flight analyser (Q-TOF). 
When ions are moving towards the analyser, smaller ions will move faster than bigger 
ions, the time that each ion will take to move towards the detector is called Time Of 
Flight (TOF) from this parameter the m/z value of each ion can be determined. In 
quadrable mass analyser, varying radiofrequency allows for selection of a specific m/z 
ratio. The Synapt G2 Q-TOF instrument used in this study is a ‘hybrid’ high resolution 
mass spectrometer combining quadrupole technologies with a time-of-flight mass 
analyser 19. 
The goal of the reported study in this chapter is the successful purification of major 
cyclodecapeptides from the biologically produced or commercial tyrothricin complex. 
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This was accomplished by the production of the tyrothricin complex from the soil 
bacterium, followed by, isolation and characterisation of Trcs single analogue within 
the biological or commercial tyrothricin complex. Trc A, B, C, as well as TpcB and C 
were successfully produced and purified to the purity of >90%, as determined by 




Tyrocidines were purified from the tyrothricin complex produced by Br. parabrevis 
ATCC 8185 obtained from the American Type Culture Collections (Manassas, VA, 
USA). The medium used for peptide production was made up from tryptone soy broth 
(TSB), agar, D-glucose, tryptone, monopotassium phosphate (KH2PO4), magnesium 
sulphate (MgSO4), calcium chloride (CaCl2), ferric sulphate (FeSO4), manganese 
sulphate (MnSO4), sodium chloride (NaCl), obtained from Merck (Darmstadt, 
Germany). Potassium chloride (KCl) was supplied by Sigma-Aldrich (St Louis, USA). L- 
amino acids (L-tryptophan and L-phenylalanine) were purchased from Lurgi (Frankfurt, 
Germany). The media was filter sterilised using mixed cellulose syringe filters (0.22 
µm) purchased from Merck-Millipore (Massachusetts, USA). 
The purification of tyrocidines from the tyrothricin complex was achieved using the 
following organic solvents: Methanol (MeOH) and trifluoroacetic acid (TFA, >98%) 
supplied by Sigma-Aldrich (St Louis, USA), ethanol (EtOH), diethyl ether (DEE) and 
acetone were supplied by Merck (Darmstadt, Germany) and acetonitrile (HPLC-grade) 
was from Romil Ltd (Cambridge, United Kingdom). Activated carbon was purchased 
from Lurgi (Frankfurt, Germany). Analytical grade water was prepared by filtering 
water from a reverse osmosis plant through a Milli-Q® water purification system 
(Milford, USA). Phosphorous pentoxide and commercial tyrothricin extract were 
obtained from Sigma-Aldrich (St Louis, USA). The Nova-Pak HR C18 RP-HPLC semi- 
preparative column (6 µm particle size, 300 mm x 7.8 mm), C18 Nova-Pak® analytical 
RP-HPLC column (5 µm particle size, 150 mm x 3.9 mm), and Acquity HSS T3 (2.1 × 
150 mm; 1.8 µm particle size) UPLC columns were from Waters (Milford, USA). 
Falcon® tubes and Petri dishes, supplied by Becton Dickson Labware (Lincoln Park, 




2.3.1 Production of the cyclodecapeptides 
A. Pre-Culturing of B. parabrevis as a producer of tyrocidines 
 
A freezer stock of B. parabrevis 8185 was plated onto TSB agar plates (3% m/v 
TSB,1.5% m/v agar) using sterile culturing techniques and incubated for ±48 hours at 
37 °C. This was followed by the re-streaking of the fast-growing brown colonies on 
another TSB plate and the incubation at 37 °C for ±48 hours. 
B. Production of the tyrothricin complex from B. parabrevis 
 
Overnight cultures containing single colonies of B. parabrevis in 20 mL TSB media 
were used to inoculate TGS media supplemented by phenylalanine (20 mM) and 
tryptophan (10 mM). The inoculated media were left to incubate for 10 days at 37°C as 
described by Vosloo et al. 20. 
C. Extraction of selected cyclodecapeptides from the tyrothricin complex 
 
The optimised methodologies that were used to extract the crude peptide mixture from 
the Br. Parabrevis cultures were developed by the BIOPEP Peptide Group 
(Stellenbosch, South Africa) and cannot be discussed in detail as the technology is 
protected under a non-disclosure agreement. In short, the cultures were acidified, 
extracted with an organics solvent, precipitated, and polished to remove the brown 
pigments resulting in the extraction of a peptide complex (tyrothricin). 
The tyrothricin extract contains a combination of Trcs and Grms 3, 21. The gramicidins 
were removed by washing several times with a mixture of ether and acetone 1:1 (v/v) 
and centrifuging at 3000×g for 10 minutes to collect the pellet 11, 20. The Trcs- 
containing pellet was first dried with nitrogen gas to remove the ether: acetone solution 
before it was re-suspended in 50% (v/v) acetonitrile: analytical quality water and 
freeze- dried for further analysis and purification. The removal of Grms was confirmed 
through UPLC-ESMS analysis. 
2.3.2 Semi-preparative HPLC purification of selected 
cyclodecapeptides 
Single analogues of TrcA, B, C, TpcB, and TpcC were obtained through semi- 
preparative RP-HPLC. The purification was done using a chromatographic system
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controlled by Millennium software comprising of a Waters 717 Plus Autosampler, two 
Waters 510 pumps, and a Waters 440 detector set at 254 nm. The temperature of the 
column was set at 35°C. 
Peptide extracts were dissolved in 50% (v/v) acetonitrile: analytical water at 10 mg/mL, 
centrifuged at 3000 g for 10 minutes to remove particulate matter and injected at 100 
µL per purification run onto a reverse-phase semi-preparative C18 Nova-Pak® column 
(6 µm particle size, 60 Å pore size, 7.8 mm x 300 mm). Solvent A (0.1% v/v TFA: 
acetonitrile: analytical quality water) and solvent B (90% v/v ACN, 0.01% v/v TFA) 
were used for the separation of the peptide in the Trcs extract using a gradient elution 
programme (Table 2.2) at 3.0 mL/min flow rate. Fractions were collected and dried in 
pyrolysed 20 mL vials and stored tightly closed at room temperature 22. 
Table 2.2 The HPLC gradient program utilised for semi-preparative HPLC purification of the 
selected cyclodecapeptides from Br. parabrevis. 
 
Minutes % Eluent A % Eluent B Curve* 
0.00 50 50 none 
0.50 50 50 6 linear 
23.0 20 80 5 concaves 
24.0 0 100 6 linear 
26.0 0 100 6 linear 
30.0 50 50 6 linear 
35.0 50 50 6 linear 
* Curves 5 and 6 are from WatersTM gradient programmes 
 
 
2.3.3 Characterisation of peptide extracts and purified peptides by 
ES-MS and UPLC-MS analysis 
All fractions with more than 1.0 mg material from the purification steps were analysed 
using ESMS and UPLC-MS. All samples were subsequently centrifuged at 8600 x g 
for 10 min to remove any particulate material. 
The system consists of a Waters Acquity® UPLC coupled to the high-resolution 
Waters Synapt G2 quadrupole time-of-flight (Q-TOF) mass spectrometer. For direct 
ESMS injections and detection during UPLC-MS, the instrument parameters were as 
follows: the cone and capillary voltages were set to 15 V and 3 kV respectively, 
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samples from direct injection (2-5 µL were injected via Acquity® UPLC system) and 
UPLC-MS were passed via a Z-spray electrospray ionisation source at a set 
temperature of 120 °C and flow of 300 L/minute, desolvation at 275 °C and nitrogen 
gas at 650 L/hour flow rate into the mass analysers. Continuum data were collected in 
positive mode from m/z of 300-2000. For direct ESMS analysis, the concentration of 
peptide samples ranged between 250 -1000 µg/mL in 50% acetonitrile: analytical 
quality water, depending on purity. 
For UPLC-ESMS 3 µL of the peptide sample, at 250 and 1000 µg/ in 50% acetonitrile: 
analytical quality water for purified HPLC fractions and crude extracts respectively, 
were injected onto an Acquity UPLC® BEH C18 column (130Å pore size, 1.7 µm 
particle size, 2.1 mm diameter X 50 mm length) at a flow rate of 0.3 mL/min and a set 
temperature of 60°C before introduction to the mass spectrometer. The separation 
was achieved using the linear-gradient program, given in Table 2.3 11. 
Table 2.3 The UPLC-ESMS gradient program peptide extracts and purified cyclodecapeptides 
 
Minutes % Eluent A % Eluent B Curve* 
0.00 0 0 6 
0.50 100 0 6 
1.00 70 30 6 
10.0 40 60 6 
15.0 20 80 6 
15.1 0 0 6 
18.0 100 0 6 
*6 depicts linear curve from WatersTM gradient programmes 
 
The relative purity of the extracts was calculated from the peak area obtained from 
UPLC-ESMS, whereas the identity and integrity of peptides present in purified extracts 
were confirmed using high-resolution ESMS. The data obtained from ESMS and 
UPLC-ESMS was analysed using MassLynx™ software V4.1. In order to analyse the 
peptide identity and integrity, the m/z values in addition to the MaxEnt 3 calculated 
monoisotopic Mr of each peptide was assessed and evaluated using parts per million 
(ppm) mass error. The following equations were used to calculate the ppm mass error: 
ppm = 






2.4 Results and discussion 
2.4.1 Analysis of amino acid supplemented crude extracts 
A complex mixture consisting of tyrocidines, tryptocidines, and phenycidines, as well 
as linear Grms, was successfully extracted from the tyrothricin complex produced by 
the soil bacterium Br. parabrevis. The exact composition of these crude extracts and 
the success of supplementation were monitored by UPLC-ESMS. The UPLC-ESMS 
chromatogram of each supplementation is shown in Figures 2.1-2.3. 
Due to the highly conserved structure of tyrocidines, the analogues differ from one 
another by only one or two aromatic amino acids residues. The similarity between 
different tyrocidine analogues makes the purification of a single analogue a relatively 
challenging task 11. Supplementation of the culture media with Phe and Trp shifted the 
profile of peptides produced by Br. parabrevis ATCC 8185 towards TrcA and TpcC, 
analogues respectively and therefore simplify the purification. This result correlates 
with the previous findings by Vosloo et al 20. 
Phe supplementation (20 mM Phe) of the bacterial culture media resulted in the 
production of a wide range of A analogues from the tyrocidine, tryptocidines, and 
phenycidine families with TrcA being the major peptide analogue (Figure 2.1). The 
low resolution between TrcA (Rt=10.21) and TrcA1 (Rt=10.09) or TpcA (Rt=10.74) and 
PhcA (Rt=10.68) makes the purification difficult. However, TrcB is a good candidate 
to be subjected to RP-HPLC. Despite the small amount of TrcB (low signal intensity), 
there is no co-elusion if the production of TrcB’ with the inversion of residues 3 and 4 
is limited. 
Table 2.4 shows that TrcA>TpcA>Grms/TrcB>TrcA1>PhcA was the pattern of 
analogue abundancy presented in 20 mM Phe supplemented cultures. Furthermore, 
this culture had lower production of Grms when compared to cultures receiving no 
supplementation. TrcA1 and PhcA are present in this culture while they are not in non- 
supplemented culture contrasting the Tpc analogues which are present in non- 
supplemented. 
Trp-supplementation (10 mM Trp) of the bacterial culture media resulted in the 
production of C analogues of the tyrocidine and tryptocidine families with TpcC being 
the major peptide analogue (Figure 2.2). There is less co-elusion between different
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analogues of Tpcs, therefore these bacterial culture extracts are good candidates to 
be subjected to RP-HPLC for TpcC, TrcC, and TpcB isolation. TrcB would have a low 
yield due to the very low amount present in the 10 mM Trp-supplemented culture (1% 
of the total culture mass) while TpcC is expected to have the highest yield after 
purification (27% of the total peptide). Furthermore, supplementation caused an 
increase in Grms production when compared to 10 mM Phe supplementation and un- 
supplemented cultures (Table 2.4). TpcC>Grms>TrcC>TpcB>TrcB was found to be 
the pattern of analogues abundancy presented in 10 mM Trp-supplemented cultures. 
In contrast to the supplemented bacterial cultures, the culture which received no amino 
acid supplementation (Figure 2.3), did not favour the predominant production of 
analogues from any one of the A, B, and C groups. Instead, a mixture of A, B, and C 
analogues belonging to all three tyrocidine, tryptocidines, and phenycidine families 
was produced. However, TrcB was the most abundant analogue within the crude 
peptide mixture. The HLPC purification had sufficient resolution and different 
analogues present in this culture have been separated well from one another except 
PhcA (Rt=10.18) and TpcA (Rt=10.26). TrcB, TrcA are good candidates to be 
subjected to RP-HPLC as there are high amounts in the culture and there is no co- 
elusion. However, TpcC will have a low yield due to the very low amount present in 
the culture (4% of the total culture). 
Table 2.4 shows that TrcB>TrcA>TpcB>TrcC>TpcA>TpcC is the pattern of analogues 
abundancy presented in extracts of non-supplemented cultures. 
The abundancy pattern of Trcs analogue present within the supplemented cultures 
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Figure 2.1 The UPLC-ESMS profile (top left) of all the different peptides present in crude 
extract from production in 20 mM Phe supplemented culture. Extracted m/z ([M+2H]2+) 
chromatograms of component peaks in each of the crude extracts indicate the main analogue 
in the extracted peaks. The retention time and peptide identity for each of the single analogues 






















































































Figure 2.2 The UPLC-ESMS profile (top) of all the detected peptides and mass extracted 
chromatograms of crude extract from 10 mM Trp supplemented culture media. The single 
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Figure 2.3 The UPLC-ESMS chromatogram (top left) of all the detected peptides and mass 
extracted chromatograms of crude extract from non-supplemented culture media. The 


































Table 2.4 Summary of percentage abundance of single analogues presents in the crude 
peptide mixtures extracted from amino acid supplemented and non-supplemented bacterial 
cultures of Br. parabrevis. 
 
 % abundance a 
Peptide identity 
10 mM Trp 
supplemented 



















TrcC 7.2 - 7.7 
TrcC1 
TpcA 
- - - 









- 2.7 - 
14.8 4.2 8.5 
% Total peptideb 41.6 50.6 79.6 
a % Abundance was calculated by expressing the peak area of each peptide as a percentage of the 
sum of the peak areas of all peptides present in the extract. It was assumed that the response factors 
of all peptides are similar due to their analogous structures. 
b %Total peptide was determined by the sum of the peak areas of all the Trcs present in the crude 
extract. 
 
2.4.2 Purification of cyclodecapeptides from culture extracts 
Tyrocidines and analogues were extracted and purified through four different steps 
which resulted in the removal of linear Grms and non-peptide material. UPLC-ESMS 
analysis of non-supplemented bacterial culture, as an example, shows the resultant 
profile of each step (Fig. 2.4). The UPLC-ESMS analysis in Fig. 2.4 of stepwise 
purification showed that each step resulted in the removal of more of Grms (Rt=14- 
16.5 minutes) and non-peptide material (Rt=2.5-6.5 minutes). The organic solvent 
extraction resulted in a characteristic tyrothricin profile containing some non-peptide 
material, and the Trcs, Tpcs as well as the Grms (Fig. 2.4A) with TrcB being the major 
analogue. The precipitation step did not lead to a major change in the profile but did 









































































Figure 2.4 The UPLC-MS chromatography of stepwise purification of non-supplemented Br. 
parabrevis culture media. Peptide extract after A. organic solvent extraction B. precipitation 
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The polishing step led to the loss of more polar peptides such, as TrcC and TrcB. The 
DEE-acetone precipitation removed most contaminants and Grms but led to a major 
loss of in particular the tryptocidines, with the tyrocidines (TrcA>TrcB>TrcC) remaining 
as the abundant analogues. The removal of Grms is essential as it complicates the 
purification of the other peptides (Trcs and Tpcs) during HPLC. The Grms are very 
hydrophobic and tend to stick and accumulate on the C18 matrix leading to leaching 
and loss of column resolution (unpublished results from BIOPEPTM Peptide Group). 
A summary of the purification yields is given in Table 2.5. Although there is a significant 
decrease in the mass yield of the peptide extract, the purity of different Trc-fraction 
increases to above 95%. Isolation of TrcB and TrcC analogues via RP- HPLC from the 
crude extract before the polishing step is more feasible while the TrcA analogue can be 
isolated with a greater yield from the crude extract after being washed by DEE- 
acetone. The predicted mass yields of the major analogues within the un- 
supplemented culture are tabulated in Table 2.6. For the major peptide analogues, 
more than 60% of their mass were lost during the four steps in purification with losses 
of TrcB, TrcC, TpcA, and TrcA of 95%, 84%, 82%, and 62% respectively. 
 
Table 2.5 Summary of the mass yields, % purity, and the relative yield % after four-step 










Organic extraction 661.3 79.0 100 
Precipitation 297.9 85.5 48.8 
Polishing 235.4 92.2 41.6 
DEE: Acetone wash 107.7 94.1 19.4 
a The %purity was determined by the sum of the peak area of all peptides present in the crude extract after each 
step of organic solvent purification 
b The % mass yield determined from the crude culture extracted after each step relative to the first step 
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Table 2.6 The predicted mass yields of the most predominant analogue in non-
supplemented culture media. 
 
 Theoretical mass (mg) yield of the major analogue a 
Step 
Organic extraction 
TrcA TrcB TrcC TpcA 
131 203 50.9 46.3 
75.4 88.5 27.9 22.3 
71.1 50.9 19.8 21.7 
48.9 8.9 7.9 8.0 
Precipitation 
Polishing 
DEE: Acetone wash 
aThe mass (mg) of the predominant analogues present in the non-supplemented culture was calculated by 
multiplying of % abundance by the total mass (mg) (refer to Table 2.7) of the crude extract after each step of the 
organic solvent purification 
 
 
The percentage abundance of most Trcs analogue (TrcC, TpcA and TpcC) remained 
consistent through all four steps of purification unlike TrcB, which was lost by a further 
amount after each step of purification relative to the other analogue. TrcA was the only 
analogue that had a significant increase in percentage abundance after all four 
purification steps (Table 2.7). 
In order to purify further amount of Trcs single analogues, commercial tyrothricin 
complex was washed with ether: acetone and subjected to RP-HPLC. The insolubility 
of Trcs analogues and solubility of the hydrophobic Grms in DEE-acetone due to their 
different hydrophobic properties allowed for the separation of the two groups of 
peptides from the tyrothricin mixture. However, as previously noted with non-
supplemented culture, DEE-acetone wash, results in loss of the Trcs analogues. 
Therefore, each complex (tyrothricin, Trcs and Grms) were subjected to UPLC-ESMS 
to compare the abundance of different peptides analogues present within the 
preparation (Figure 2.5). 
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Table 2.7 The percentage abundance of Trc single analogues and Grms in non-supplemented 
Br. parabrevis culture media after each organic solvent step of extraction and purification. 
 











TrcA 19.8 23.1 29.2 45.4 
TrcA1 - - - - 
TrcB 30.7 27.6 28.6 21.6 
TrcB1 - - - - 
TrcC 7.7 9.4 8.4 7.2 
TrcC1 - - - - 
TpcA 7.0 7.5 9.3 7.4 
TpcB 9.1 15.7 12.8 8.3 
TpcC 3.6 4.5 3.7 3.4 
PhcA - - - - 
Grms 8.5 6.7 3.0 2.8 
%Total b 77.9 87.7 92.0 93.3 
a% Abundance was calculated by expressing the peak area of each peptide as a percentage of the sum of the 
peak areas of all peptides present in the extract. It was assumed that the response factors of all peptides are similar 
due to their analogue structure. 
b %Total peptide was determined by the sum of the peak areas of all the Trcs present in the crude extract after 
each step of purification. 
 
 
The DEE-acetone wash resulted in complete loss of minor analogues and significant 
loss of some of the major analogues present within the culture despite increasing the 
total purity by removing the Grms. Table 2.8 compares the pattern of abundancy 
different Trcs analogues present in Trc mix and Grms extracted from the tyrothricin 
complex. In the tyrothricin complex, the major analogue was TrcB, if the peptide loss 
was even for all different Trcs analogues it was expected of TrcB to remain the major 
analogue present in extracted Trc complex and Grms. However, the major analogue 
present within the extracted Grms is TrcC. Therefore, it is concluded that the major 





Figure 2.5 The UPLC chromatograms of commercial tyrothricin complex with A. the untreated 
tyrothricin, B the precipitate of the DEE: acetone wash containing the Trc mix, and C. the 
































Table 2.8 The percentage abundance and theoretical mass (mg) yield of the major analogue 
of Trc single analogues and Grms present within the commercial tyrothricin complex before 




Theoretical mass (mg) yield of 




































14.2 12.4 11.2 
 
13.6 15.0 13.1 
 
1.1 1.2 0.5 
 
1.5 2.9 1.8 
 
14.4 9.3 13.1 
 
15.2 22.9 9.7 
 
3.9 - 6 
 
2.7 3.8 1.7 
 
9.9 10.4 10.6 
 
9.6 13.0 9.3 
 
0.7 1.4 - 
 
2.2 - 5.6 
 
4.1 - 6.7 
 
1.8 - 3.1 
2.13 1.27 0.52 
 
2.04 1.53 0.61 
 
0.17 0.12 0.02 
 
0.23 0.3 0.08 
 
2.16 0.95 0.61 
 
2.28 2.34 0.45 
 
0.59 - 0.28 
 
0.41 0.27 0.08 
 
1.49 1.06 0.49 
 
1.44 1.32 0.43 
 
0.11 0.1 - 
 
0.33 - 0.26 
 
0.62 - 0.31 
 













































a % Abundance was calculated by expressing the peak area of each peptide as a percentage of the 
sum of the peak areas of all peptides present in the extract. It was assumed that the response factors 
of all peptides are similar due to their analogue structure. 
b %Total Trcs was determined by the sum of the peak areas of all the Trcs present in the tyrothricin 
complex and each of the extracts. 
c The mass (mg) of the predominant analogues presents in the tyrothricin complex and each of the 
extracts were calculated by multiplying of % abundance by the total mass (mg) of in the tyrothricin 
complex and each of the extracts. 
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2.4.3 Effect of time on aggregation and purification 
It has been shown by various studies 23, 24 that Trcs form oligomers in a variety of 
structures over a time which significantly complicates the purification and isolation of 
Trcs single analogues. Peptides with higher purity and hydrophobicity have a higher 
tendency of oligomerisation. 
Trcs form different oligomers including dimers, trimers, and tetramers that can be 
detected by ESMS. The ESMS spectra in Figure 2.6 shows the oligomerisation profile 
of commercial Trc mix. As many of the dimers and higher oligomers are hetero- 
oligomeric which complicates the analysis as many heterodimers and homodimers, 
such as TrcA-TrcC and TrcB-TrcB, have the same mass. It is therefore difficult to 
distinguish the identity of different monomers present within a hetero-oligomeric 
complex without advanced mass spectroscopic analysis. When purifying Trcs it will 
typically take about 12 hours a day with 20 semi-preparative HPLC runs (35 minutes 
each) and peptides that are aggregating complicates purification. Highly aggregated 
peptides result in peak broadening in which different analogues of Trcs co-elute at the 
same time as well as a shift in retention time. Furthermore, aggregated peptide 
preparations can cause technical difficulties during the purification. Peptide 
aggregates tend to precipitate out of the solution and those that remain in solution as 
oligomers have an altered hydrophobicity which results in a shift in RP-HPLC 
chromatographic profile. 
To test the time frame for dissolving and purification, samples were subjected to RP- 
HPLC over two time periods after being dissolved in 50% acetonitrile: analytical quality 
water. The chromatograph in Figure 2.7 shows the effect of aggregation on the elution 
time of the tyrocidines from the C18 column during one run of RP-HPLC. It seems that 
the formation of different oligomers of tyrocidines over six hours has resulted in more 
hydrophobic structures that caused broader peaks and later elusion from the C18 
column when compared to the fresh sample with less oligomeric structures. However, 
the resolution between the three groups of Trc A1/A, B1/B, and C1/C was maintained, 
indicating that the formation of hetero-oligomers did not have a major influence over 











































500       750      1000    1250    1500    1750    2000     2250    2500 
 








5500    5750 
 
Figure 2.6 ESMS mass spectrum derived via MassLynx 4.01 MaxEnt 3 algorithm showing 
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Figure 2.7 Semi-preparative HPLC chromatograms of a 100 µL injection of commercial Trc 
mixture (5 mg/mL). A. RP-HPLC profile of Trc mix directly after dissolving in in %50 
acetonitrile: water B. RP-HPLC profile of Trc mix six hours after preparation C. The overlay of 


































































2.4.4 Semi-preparative RP-HPLC purification of single 
cyclodecapeptide analogues 
The crude extracts and commercial Trc-mix were further purified using RP-HPLC 
based on a method developed by Rautenbach et al. 4 and Eyeghe-Bickong 21. The 
protocol allows the earlier elution of most hydrophilic analogues and later elution of 
the most hydrophobic analogues, with the following elution sequence of the major 
peptides in this study: TrcC, TpcC, TrcB, TpcB, TrcA, and PhcA. The hydrophobicity 
of the peptide depends on the identity of aromatic residues at positions 3, 4, and 7. 
Figure 2.8 shows the collected fractions from the three different culture extracts in 
addition to the commercial Trc-mix. 
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Figure 2.8 Semi-preparative HPLC chromatograms of A. commercial Trc-mix after the 
wash with DEE: acetone, B. 20 mM Phe supplemented C. non-supplemented. D. 10 mM 
Trp- supplemented cultures after the organic solvent extraction and precipitation step. The 
collected fractions are indicated with dashed lines and annotated with lower case a-f. 
 
There is an elution time difference between Trcs single analogue present within 
commercial Trc-mix and biological culture about (4 minutes). This is because the 
biological culture extracts have been purified utilising a different more modern HPLC 
instrument than commercial Trc mix. The peptide composition of all collected fractions 
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Table 2.9 Summary of the ESMS analysis of each of the semi-preparative HPLC fractions 
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a The fraction annotation refers to the chromatogram in Fig 2.8 (A, B, C or D) and fraction (a-f) 
b Experimental Mr calculated using the following equation: Mr = (m/z x z)– z x 1.007825. 
c  Parts per  million error or ppm errors were calculated using the following equation: 
ppm = 106 x {Mr(theoretical) – Mr(experimental)}/Mr(theoretical). 
ND - Not Determined: The amount of collected fraction was too low for ESMS analysis, therefore the 
peptide identity in the collected fraction is unknown. 
 
From the initial ESMS analysis (Table 2.9) it was found that fractions c and f (from 20 
mM Phe-supplemented culture extract) containing pure TrcB and TrcA, respectively, 
fractions b and d (from 10 mM Trp-supplemented culture extract) containing pure 
TpcC and TpcB, fractions a and f (from non-supplemented culture extract) 
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containing pure TrcB and TrcA. Therefore, they were subjected to UPLC-ESMS to 
determine the purity of the single analogues. One example UPLC-MS from each of the 
purified peptides is shown (Figures 2.10). 
Our group previously showed that Trcs tend to deaminate at the Glu and/or Asn 
residues and as many peptides, they have a tendency of K+ or Na+ adducts formation 
during ESMS. These aspects could influence the purity and UPLC-MS purity 
determination of the purified Trcs and Tpcs. ESMS results revealed that none of the 
pure peptides in the collected fractions were deaminated. Interestingly, a novel 
glycosylated analogue of TpcC was detected in fraction a purified from the 10 mM Trp- 
supplemented culture extract. Calculated mass error for all analogues present within 
different collected fractions was below 6 ppm confirming the correct identification of 
the peptides in the tyrothricin complex (Tables 2.9 and 2.10). The UPLC-MS 
chromatography correlated with similar reported studies 21, 24, 25 (Table 2.10). 
Fraction a, containing mainly TrcC, and fraction c containing mainly TpcC from the 10 
mM Trp supplemented culture were contaminated by small amounts of Trc B and 
TpcB, respectively. Fraction d, mainly containing TrcB, purified from non-
supplemented culture contained a small amount of TpcC as shown in the UPLC-
ESMS chromatogram in Figure 2.3. The retention time of TrcB (8.73) and TpcC (8.56) 
is very close therefore some co-elution of the two peptides was to be expected in the 
lower resolution semi-preparative RP-HPLC. 
Fractions a and c containing mainly TrcB and TrcC (from Trc mix) contained a small 
amount of the Lys analogues, TrcB1 and TrcC1, respectively. Separation of TrcC from 
TrcC1 and TrcB from TrcB1 is difficult as the two analogues only differ in a CH2 group 
due to the substitution of Orn by Lys. In order to obtain a better separation analytical 
RP-HPLC can be utilised with lower loading concertation, lower flow rate, and higher 
resolution 5, 24. 
The purification of five different Trcs single analogues from the crude extracts and 
commercial Trc mix was successful. All analogues had a purity of higher than 90%, as 
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Figure 2.9. UPLC-MS results of the purified peptides with A. the UPLC profile of the purified 
peptide. B. ESMS positive ion spectrum of the major peak indicating singly charged 
molecular ions [M+H]+ and doubly charged molecular ions [M+2H]2+ and C. the MaxEnt 3 
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Mass spectrometric analyses revealed that all five single analogues of Trcs have a 
high tendency of forming singly and doubly charges species which is due to the single 
and double protonation of the peptide (Figure 2.9). It is clear from the mass 
spectrometry analysis that the five Trcs analogue that were purified are of high purity 
with expected Mr (Figure 9.2, Table 2.10). 
















TrcA F-sup/Trc mix f 10.3 0.1 11.51 92 
TrcB Un-sup/Trc mix d 1.4 -3.5 10.24 90 
TrcC Un-sup a 1.6 -0.3 9.41 96 
TpcB W-sup e 2.6 -1.9 10.22 94 
TpcC W-sup d 4.2 0.3 10.70 90 
* F-sup, W-sup and un-sup depicts Phe, Trp and non-supplemented cultures, respectively. 
a Experimental monoisotopic mass was determined by ESMS and the MaxEnt3 algorithm of each peptide. 
b % Purity was calculated by expressing the peak area of each peptide as a percentage of the sum of the UPLC- 
MS peak areas of all compounds present in the extract. It was assumed that the response factors of all peptides 
























































Trcs tend to self-assemble at high concentrations and over time which severely 
complicates the RP-HPLC purification of these closely related cyclodecapeptides. 
Aggregation results in inconsistent retention and peak broadening of different Trc 
analogues during the RP-HPLC purification. Regardless of these aggregation issues, 
five single analogues, TrcA, TrcB, TrcC TpcB and TpcC, with the purity of above 90% 
were successfully isolated from the tyrothricin complexes produced by Br. parabrevis 
and commercial tyrothricin complex. The supplementation of the Br. parabrevis culture 
broths with 20 mM Phe and 10 mM Trp shifted the production towards TrcA and TpcC, 
respectively. This correlated with previous studies by Vosloo et al. 20. Furthermore, 
UPLC-ESMS showed the presence of minor Lys containing analogues, TrcA1, TrcB1 
and the rare PhcA1, Orn containing including Tpcs (TpcA, TpcB, TpcC) and Trcs (TrcA, 
TrcB, TrcC) in crude culture extracts. The effect of supplementation on the Trp-rich 
Grms was to be expected with 10 mM Trp-supplementation increasing Grms 
production, in contrast to 20 mM Phe-supplementation decreasing Grms production. 
The reason for this is probably the high Phe concentration promoting Phe-containing 
Trc synthesis, while the Trp-rich Trcs, Tpcs, and Grms being compromised. Although 
supplementation eased the isolation of single Trc analogues, it had a negative effect 
on the amount of peptide being produced, compared to the non-supplemented extract 
which was higher than the Trp/Phe-supplemented extracts. 
The four purification steps on the crude extracts resulted in the removal of linear Grms 
and non-peptide material, however, the peptide yield decreased drastically after each 
step of purification due to the loss of Trcs, some analogues were lost more than others. 
The major Trc analogues in the extract change drastically after the polishing step and 
more so after the DEE-acetone precipitation step. For example, TrcB was the major 
analogue after organic solvent extraction, while TrcA was the major analogue when 
the extract went through all four steps. The DEE-acetone precipitation step resulted in 
the removal of all linear Grms from the tyrothricin complex, however, it caused major 
Trcs analogue loss with TrcA being the major lost peptide during this step. It can be 




The isolated Trc single analogues will be used in a formulation study with a focus to 
improve their selectivity towards Candida albicans and Candida glabrata reported in 
Chapter 5. Furthermore, the effect of the formulants consisting of cellulose derivatives 
on the self-assembly of pure Trcs and Tpcs will be reported. 
 
2.6 References 
1 Rautenbach, M., Troskie, A. M., and Vosloo, J. A. (2016) Antifungal peptides: To 
be or not to be membrane active. Biochimie 130, 132–145. 
2 Hotchkiss, R.D., and Dubos, R. J. (1941) The isolation of bactericidal substances 
from cultures of Bacillus brevis. J. Cell. Biol. 141, 155-162. 
3 Dubos, R. J. (1939) Studies on a bactericidal agent extracted from a soil Bacillus: 
III Preparation and activity of a protein-free fraction. J. Exp. Med. 70, 249–256. 
4 Rautenbach, M., Vlok, N. M., Stander, M., and Hoppe, H. C. (2007) Inhibition of 
malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide 
antibiotics from Bacillus brevis. Biochim. Biophys. Acta Biomembr. 1768, 1488– 
1497. 
5 Leussa, N. A. (2014) Characterisation of small cyclic peptides with anti-listerial 
and anti-malarial activity. PhD Thesis, Department of Biochemistry, University of 
Stellenbosch, Stellenbosch, South Africa, http://hdl.handle.net/100191/86161 
6 Troskie, A. M., de Beer, A., Vosloo, J. A., Jacobs, K., and Rautenbach, M. (2014) 
Inhibition of agronomically relevant fungal phytopathogens by tyrocidines, cyclic 
antimicrobial peptides isolated from Bacillus aneurinolyticus. Microbiology. 160, 
2089–2101. 
7 Rautenbach, M., Troskie, A. M., Vosloo, J. A., and Dathe, M. E. (2016) Antifungal 
membranolytic activity of the tyrocidines against filamentous plant fungi. 
Biochimie 130, 122–131. 
8 Troskie, A. M., Rautenbach, M., Delattin, N., Vosloo, J. A., Dathe, M., Cammue, 
B. P. A., and Thevissen, K. (2014) Synergistic activity of the tyrocidines, 
antimicrobial cyclodecapeptides from Bacillus aneurinolyticus, with amphotericin 
B and caspofungin against Candida albicans biofilms. Antimicrob. Agents 
Chemother. 58, 3697–3707. 
9 Brewer, D., Hunter, H., and Lajoie, G. (1998) NMR studies of the antimicrobial 
salivary peptides histatin 3 and histatin 5 in aqueous and nonaqueous solutions. 
J. Cell. Biol. 76, 247–256. 
10 Dubos, R. J., and Hotchkiss, R. D. (1941) The production of bactericidal 
substances by aerobic sporulating bacilli. J. Exp. Med. 73, 629–640. 
11 Vosloo, J. A., Stander, M. A., Leussa, A. N. N., Spathelf, B. M., and Rautenbach, 
M. (2013) Manipulation of the tyrothricin production profile of Bacillus 
aneurinolyticus. Microbiology. 159, 2200–2211. 
12 Tang, X. J., Thibault, P., and Boyd, R. K. (1992) Characterisation of the tyrocidine 
and gramicidin fractions of the tyrothricin complex from Bacillus brevis using
Stellenbosch University https://scholar.sun.ac.za
2-33  
liquid chromatography and mass spectrometry. Int. J. Mass Spectrom. 122, 153– 
179. 
13 Dorsey, J. G. (1996) Liquid chromatography: Theory and methodology Anal. 
Chem. 68, 515-568 
14 Wheeler, J. f. (1993) Phase-transitions of reversed-phase stationary phases- 
cause and effects in the mechanism of retention. J. Chromatogr. 656, 317-333 
15 Tchapala, a. (1993) General view of molecular interaction mechanisms in 
reversed-phase liquid chromatography. J. Chromatogr. 656, 81-112 
16 Hufmer, A. F. (1997) separation and analysis of peptides and protein. Anal. 
Chem. 69, 29R-57R 
17 Veenstra, T. D. (1999) electrospray ionization mass spectrometry: A promising 
new technique in the study of protein/DNA noncovalent complex Biochem. 
Biophys. Res. Commun. 257, 1-5 
18 Jonscher, K. R., and Yates, J. R., (1997) The quadropole ion trap mass 
spectrometer-a small solution to a big challenge. Anal. Chem 245, 1-15 
19 Allen, D. R, and McWhinney, B. C. (2019) Quadrupole Time-of-Flight Mass 
Spectrometry: A paradigm shift in toxicology screening applications. Clin Biochem 
Rev. 40, 135-146 
20 Vosloo, J. A. (2016) Optimised bacterial production and characterisation of 
natural antimicrobial peptides with potential application in agriculture. Ph.D. 
Thesis, Department of Biochemistry, University of Stellenbosch. 
http://hdl.handle.net/10019.1/98411 
21 Eyéghé-bickong, H. A. (2011) Role of surfactin from Bacillus subtilis in protection 
against antimicrobial peptides produced by Bacillus species. Ph.D. Thesis, 
Department of Biochemistry, University of Stellenbosch. 
http://hdl.handle.net/10019.1/6773 
22 Paladini, A., and Craig, L. C. (1954) The chemistry of tyrocidine. III. The structure 
of tyrocidine A. J. Am. Chem. Soc. 76, 688–692. 
23 Breslow, R., and Chipman, D. (1964) The use of tyrocidines for the study of 
conformation and aggregation behaviour. J. Am. Chem. Soc. 55, 4195–4196. 
24 Spathelf, B. M. (2010) Qualitative structure-activity relationships of the major 
tyrocidines, cyclic decapeptides from Bacillus aneurinolyticus. Ph.D. Thesis, 
Department of Biochemistry, University of Stellenbosch, 
http://scholar.sun.ac.za/handle/10019.1/4001 
25 Troskie, A. M. (2013) Tyrocidines, cyclic decapeptides produced by soil bacilli, 
as potent inhibitors of fungal pathogens. Ph.D. Thesis, Department of 




The influence of formulants on anti-Candida activity 




Tyrocidines are small cyclic antimicrobial peptides with proven anti-Candida activity 1. These 
molecules are well-known for forming a variety of oligomeric structures, especially in 
aqueous environments 2, 3. The activity of the tyrocidines is proposed to be dependent on 
their oligomerisation profile 2, 3, 4. Modification of a peptide’s amphipathicity, hydrophobicity, 
and conformational flexibility in solution, either via chemical modification or conformational 
changes due to specific interactions with media components or oligomerisation, can 
influence the peptide’s activity 5, 6, 7. It is therefore hypothesised that formulation of 
tyrocidines could alter their conformation, oligomerisation, and biological activity 3. 
In this study, the tyrocidine peptide complex or tyrocidine mixture (Trc mix) was formulated 
with cellulose derivatives to limit the formation of large Trc oligomers 8, 9, therefore allowing 
peptide, specifically dimers, to act on the target organism which would enhance the overall 
biological activity. Formation of big aggregates/oligomers would result in the loss of peptide 
activity due to the loss of peptide from solution and possibly the loss of dimeric peptide that 
is proposed to be the active structures 7, 8. Most of the dimeric structures, which were found 
by Munyuki et al. 8 via a modelling study, retain their amphipathic properties allowing 
interaction and destabilising of the target cell membrane 2, 7, 8, 9. 
Six different cellulose derivatives and soluble chitosan were used to formulate of the Trc 
mix. In addition to A4M and E4M formulant of pure TrcA and A4M formulant of TpcC. All 
cellulose derivatives formulants utilised in this study have a cellulose backbone with different 
modifications including, methyl, propyl, and hydroxyl groups (Table 3.1). The activity of the 
formulations and peptides was tested against Candida albicans (C. albicans) and Candida 
glabrata (C. glabrata) and human erythrocytes for toxicity. To compare the activity of Trcs 
with the antifungal drugs, caspofungin and fluconazole, the % metabolic inhibition of C. 
albicans was compared with that induced by Trc mix and its cellulose-type formulations. 
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Table 3.1. Summary of commercial modified cellulose and saccharide derivatives utilised as 
formulants for the tyrocidine mixture (Trc mix) in this study. The colours in this table will be used to 
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Commercial tyrothricin extract was supplied by Sigma-Aldrich (St Louis, USA). Trc mix was 
extracted from commercial tyrothricin using an optimised diethyl ether and acetone 
precipitation protocol 10. Ethanol (EtOH), diethyl ether (DEE), and acetone were supplied by 
Merck (Darmstadt, Germany). Tyrocidine a (TrcA) and tryptocidine C (TpcC) were purified 
to >95% from Trc mix and Brevibacillus parabrevis culture extracts (refer to Chapter 2 for 
more details on purification). Chitosan, gramicidin S (GS), fluconazole and caspofungin was 
purchased from Sigma-Aldrich (St Louis, USA). Analytical grade water (MQH2O) was 
prepared by filtering water from a reverse osmosis plant through a Millipore-Q® water 
purification system (Milford, USA). The 96-well black and transparent flat-bottom plates were 
supplied by Thermo Fisher Scientific (Denmark). Benecel A4M (A4M), Benecel E4M (E4M), 
Benecel E10M (E10M), Benecel K15M (K15M) Klucel E IND (KLUE), Klucel I IND (KLUI) 
were donated by ASHLAND, Covington, Kentucky America. Sterile Petri dishes were 
obtained from Lasec (South Africa) and Falcon tubes were supplied by Becton Dickson 
Labware (Lincoln Park, USA). Agar, sodium chloride, hydrochloric acid, tryptone, and yeast 
extract were obtained from Merck (Darmstadt, Germany). RPMI 1640 medium was from 
Lonza (Walkersville, USA) and resazurin sodium salt was from Sigma Aldrich (St Louis, 
USA). Mixed cellulose syringe filters (0.22 µm) were purchased from Merck-Millipore 
(Massachusetts, USA). C. albicans CAB1653, an environmental isolate from the Western 
Cape, South Africa, was obtained from the culture collection of Prof. Alf Botha in the 
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Department of Microbiology, Stellenbosch University, South Africa. C. glabrata BG19, a 
clinical isolate, was donated by Dr Bahareh Bagheri, Tygerberg Medical School, 




3.3.1 Culturing of C. albicans and C. glabrata 
Yeast cells from freezer stocks of C. albicans and C. glabrata were plated onto YPD agar 
plates (yeast extract 1%, peptone 2% (m/v) agar, glucose 2% (m/v) agar, 1.5% m/v agar) 
using sterile culturing techniques and incubated for ±48 hours at 37°C. This was followed 
by the inoculation of a single representative colony in 20 mL YPD broth and maturation for 17 
hours at 37°C on a shaker at 150 rpm. RPMI media was then used to subculture the 
yeast at a final cell concentration of 5.5x105 cells/mL. 
 
3.3.2 Preparation of formulations of Trc mix and purified peptides 
Seven different cellulose derivatives were prepared to stock concentrations of 1.00, 2.00, 
and 4.00 mg/mL in MQH2O. The sample solutions were then sonicated for ± 5 minutes 
allowing for a complete dissolution of the cellulose derivatives. The solutions were filter- 
sterilised using a 0.2 µm sterile filter. Trc mix, TrcA and TpcC were made up to the 
concentration of 1000 µg/mL in 15% (v/v) ethanol in MQH2O. Trc mix and the formulants 
(cellulose derivatives) were mixed in varying ratios (1:1, 1:2, 1:4, m/m) and matured for 1 
and 20 hours. TrcA and TpcC were formulated with A4M to 1:4 (m/m) ratio and TrcA was 
also formulated with E10M to 1:4 (m/m) ratio and matured for 1 and 20 hours. The 
formulations were mixed and incubated in a 96-well microtiter plate (dilution plate) and were 
serially diluted to the desired concentration. A 10 µL aliquot of the Trc mix formulations were 
transferred to another 96-well microtiter plate (assay plate) followed by the addition of 90 µL 
RPMI media containing Candida cell culture. Table 3.2 shows different formulants of Trc mix 




Table 3.2. Summary of the preparation parameters for different Trc mix formulants assay studies targeting 
two Candida species. 
 Formulants 
Trc mix: formulant 
Ratio (m/m) 
Final concentration 
of the formulant (µg/mL) 






















A4M 1:1 500 
E4M 1:1 500 
E10M 1:1 500 
KLUE* 1:1 500 
KLUI* 1:1 500 
CHS* 1:1 500 


















Water - 500 
C. albicans 
A4M 1:1 500 
E4M 1:1 500 
E10M 1:1 500 















 A4M 1:2  1000 
C. albicans 
E4M 1:2  1000 
E10M 1:2  1000 
















 A4M 1:2  1000 
C. albicans 
E4M 1:2  1000 
E10M 1:2  1000 















 A4M 1:4 2000 
C. albicans  
E4M 1:4 2000 
E10M 1:4 2000 
















 A4M 1:4 2000 
C. albicans and  
C. glabrata 
E4M 1:4 2000 
E10M 1:4 2000 
K15M 1:4 2000 
*Activity was measured at selected concentrations of Trc mix 
Stellenbosch University https://scholar.sun.ac.za
3-5  
GS, caspofungin and fluconazole, as known antifungal controls were made up to 1000 
µg/mL and were serially diluted to the desired concentration, with 10 L added to the 90 
µL C. albicans culture to a 96-well plate. The rest of the procedure was followed as 
above. 
 
3.3.3 Metabolic inhibition anti-Candida assay 
Planktonic Candida cultures, exposed to Trc mix, pure TrcA and pure TpcC and their 
formulations, as well gramicidin S, caspofungin and fluconazole, were incubated for 24 
hours at 37 °C and 90% humidity in 96-well microtiter plates. This was followed by the 
addition of 10 µL resazurin reagent (0.30 mg/mL) to each well and further maturation of 90 
minutes for C. albicans and four hours for C. glabrata (at 37 °C). The inhibition of metabolic 
activity was determined by measuring fluorescence emission of the metabolic dye using the 
Tecan Spark 10M Multimode Microplate Reader. Excitation and emission wavelengths were 
set at 560 nm and 590 nm (Em590), respectively. The measured fluorescence was 
converted to % inhibition of metabolism as described by the following equation: 
% metabolic inhibition = 100 − 
100X (𝐸𝑚590 of we𝑙𝑙 − 𝑚e𝑎𝑛 of 𝐸𝑚590 of 𝑏𝑙𝑎𝑛𝑘) 
(𝑚e𝑎𝑛 of 𝐸𝑚590 of 𝑔𝑟ow𝑡ℎ metabolism − 𝑚e𝑎𝑛 of 𝐸𝑚590 𝑏𝑙𝑎𝑛𝑘) 
 
The negative control (0% metabolic inhibition) was cell cultures treated with 1.5 % ethanol 
and the background (blank) was RPMI medium containing no cells and only the solvent 
control. 
 
3.3.4 Data analysis of metabolic inhibition assay 
Dose-response assays were done using three to four individual starter cultures, each divided 
into eight to twenty sub-cultures. All data analysis was performed using GraphPad Prism® 
V 5.0 software (San Diego, CA, USA). Non-linear regression to calculate the inhibition 
parameters utilised sigmoidal curves with variable slope (Hill slope constrained to less than 
7) were fitted to the dose-response data using the following equation: 
𝑦 = 
𝑏o𝑡𝑡o𝑚 + (𝑡o𝑝 − 𝑏o𝑡𝑡o𝑚) 
1 + 10log 𝐼𝐶50 x activity 𝑠𝑙o𝑝e 
 
The top and bottom of the curve represent the percentage metabolic inhibition at the highest 
and lowest concentrations of different formulants of Trc mix, respectively. Using the method 
described by Rautenbach et al. 11, MIC (minimum metabolic inhibition concentration), IC50 
(concentration that gives 50% metabolic inhibition) of the Candida species exposed to Trc 
mix and its formulations were determined. 
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3.3.5 Haemolytic toxicity 
The assays were performed by Dr. W. van Rensburg (Stellenbosch University) and the 
methodology is described in brief. Packed erythrocytes from a consenting anonymous A+ 
donor was obtained adhering to the relevant ethics and legislation. The haemolysis assays 
were done according to Rautenbach et al.12 with a few adaptations. Trc mix formulations 1:4 
(m/m) with the different saccharides were prepared in class vials as above and 10.0 L of 
doubling dilutions, starting at 500 g/mL, were transferred to a 96-well plate. Washed 
erythrocytes in RPMI media at 1% haematocrit (100 L) were then added to each well and 
incubated at 37°C for 2 hours. The plates were then centrifuged (900×g for 10 minutes) to 
remove the intact erythrocytes. An aliquot of 10 µL of each well’s supernatant was 
transferred to a 96-well plate containing 90 µL phosphate buffered saline. The released 
haemoglobin of the lysed erythrocytes was measured at 415 nm using a BioRad Model 680 
Microplate reader. The haemolytic toxicity was calculated using the following equation: 
% Haemolytic activity = 100 × 
𝐴𝑏𝑠 of 𝑠𝑎𝑚𝑝𝑙e − 𝑚e𝑎𝑛 𝐴𝑏𝑠 of 𝑏𝑎𝑐𝑘𝑔𝑟o𝑢𝑛𝑑 
𝑚e𝑎𝑛 𝐴𝑏𝑠 of f𝑢𝑙𝑙𝑦 𝑙𝑦𝑠e𝑑 − 𝑚e𝑎𝑛 𝐴𝑏𝑠 of 𝑏𝑎𝑐𝑘𝑔𝑟o𝑢𝑛𝑑 
 
The full lysis was determined with 10 g gramicidin S, translating to 100 g/mL in the assay 
in the lysis control wells. The negative control (background, 0% lysis) were erythrocytes in 
RPMI medium. 
 
3.4. Results and discussion 
 
This chapter aimed to find the best cellulose derivative as formulants for Trc mix, with a 
specific focus to obtain with the highest potency and specificity against C. albicans and C. 
glabrata. To achieve this aim, anti-Candia activity assays were performed on the various Trc 
mix formulation. Furthermore, fluorescence assays were performed on the most active 
formulants of Trc mix to investigate the effect of cellulose derivatives and maturation time 
on oligomerization profile of Trc mix which will be reported in chapter four. 
 
3.4.1 Assessing formulations of Trc mix targeting C. albicans 
To assess the activity of Trc mix in water containing 1.5% ethanol as control formulation. 
The activity of the Trc mix remained relatively constant between12.5- 25 g/mL when we 
considered only the MIC as inhibition parameter (Figure 3.1A), but when the full dose- 
response was considered the activity was variable (Figure 3.1B). At the low Trc mix 


































activity detected as “negative” inhibition (Figure 3.1B). At medium, to high concentration 
6.25-25 g/mL there was a variable response that could be the consequence of the Candida 
response and the variable oligomerisation of the peptides in the control preparations 2 
(Figure. 3.1B). 
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       The combined dose-response showing the activity Trc mix against C. albicans with 
[Trc mix] ranging from 100 g/mL to 3.125 g/mL. The dose response curve in A was fitted to the 
220 determinations from 11 biological repeats and 33 dose response ranges shown in B. All data 
points are shown in B with the average of 33 data points at each concentration and standard error 
of the mean is (SEM) shown in A. 
These results not only emphasised the importance of multiple biological repeats to get 
reliable data but also how important the stability of Trc mix preparation can be. To improve 
the Trc mix preparation, eight different of Trc mix preparations were prepared, namely, six 
formulations combined with commercial cellulose derivatives, one with chitosan and the 
control with Trc mix in 1.5% EtOH in water (m/v). The anti-Candida activity was measured 
for three concentrations to assess the data variability and facilitate the selection of the best 
formulant to stabilise the Trc mix. The three concentrations used were deduced from the full 
dose-response using Trc mix control preparation (Figure 3.1A). The selected concentrations 
were chosen as 50.0 µg/mL as it was the MIC* of Trc mix, 12.5 µg/mL as it is the 
approximate highest IC50, and the Trc mix MIC at 25.0 µg/mL*. 
An exploratory experiment was designed to investigate the influence of cellulose derivatives 
on Trc mix potency against C. albicans cells, with the selected concentrations of Trc mix: 
cellulose derivatives at 1:1 (m/m) ratio. Figure 3.2 shows the metabolic inhibition caused by 
different formulants of Trc mix at three different concentrations. The culture survival data 

































the metabolic dye resazurin to resorufin as cell death, while survival was equated to the 



































Control A4M E4M E10M KLUE KLUI CHS K15M 





















Control A4M E4M E10M KLUE KLUI CHS K15M 















Control A4M E4M E10M KLUE KLUI CHS K15M 
Trc mix: formulant 1:1 (m/m) 
       Metabolic inhibition of C. albicans cultures treated by A. 50 µg/mL formulated Trc mix, 
B. 25 µg/mL formulated Trc mix, and C.12.5 µg/mL formulated Trc mix. Each data point represents 


















































































At Trc mix of 50.0 µg/mL, 100% inhibition of metabolism for the seven different Trc mix 
preparations were obtained, with the control showing 2/36 cultures that survived the 
treatment (Figure 3.2A). It is hypothesised that the survival of some treated cultures may be 
due to the presence of persister cells 12. This result suggests that the formulated Trc mix at 
50 µg/mL is sufficient to eradicate persister and normal population of C. albicans, while Trc 
mix on its own only inhibited the normal population of C. albicans, and it was less effective 
or ineffective against these so-called persister cells. 
At 25.0 µg/mL Trc mix shows some scatter of data with the negative inhibition values, 
therefore only metabolic stress was induced (Figure 3.2B). It was calculated that 4-25% of 
cultures survived some of the treatments (Table 3.3), but the cells in these cultures were 
stressed which increased their metabolism and conversion of resazurin to resorufin. The Trc 
mix control preparation showed the most scatter and culture stress (19% survival), while 
there was no survival or 4-8% survival of cultures in the saccharide formulations, indicating 
saccharide formulants did enhance the anti-Candida activity of Trc mix. 
Table 3.3. Survival (%) of 24 cultures after exposure to Trc mix and its formulations with a 





   Trc mix  
25 µg/mL 
  Trc mix  
12.5 µg/mL 
Control 0.6* 19* 50* 
A4M 0 0 29 
E4M 0 0 37 
E10M 0 4 42 
KLUE 0 0 58 
KLUI 0 8 54 
CHS 0 8 46 
K15M 0 4 37 
* 36 cultures were treated for the control 
 
We observed the most stressed cells at the lowest concentration of 12.5 µg/mL Trc mix in 
the preparations, and 29-58% survival (Figure 3.2C, Table 3.3). Cultures treated with Trc 
mix formulated by cellulose derivatives with lower viscosity such as KLUE and KLUL, in 
addition to CHS show the highest survival meaning these cellulose derivatives did not 
enhance the activity of Trc mix at this concentration. The formulations of Trc mix at 12.5 
µg/mL in A4M and E4M followed by E10M and K15M, exhibiting the same or better activity 
than the control preparation, were selected for further investigation (Figure 3.2 C). 
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3.4.2 Optimising the formulation of Trc mix 
Formulation of Trc mix with A4M, E4M, E10M, and K15M enhanced the Trc mix activity as 
shown in Table 3.3 and Figure 3.2. To further assess these formulations full dose-response 
assays were performed. Trc mix was formulated with cellulose derivatives at 1:1 (m/m) ratio, 
as well as increased ratios of Trc mix: cellulose derivatives at 1:2 and 1:4 (m/m) ratio. The 
formulations were also allowed to mature over time for 1 hour (assumed as fresh) and 20 
hours (matured formulation). Furthermore, the best ratio and maturation time of the 
formulation components were selected to be tested against another species of Candida, 
namely C. glabrata. Table 3.4 gives a summary of the representative dose responses and 
comparative IC50 and MIC, values. Statistical comparison between IC50 and MIC values of 
Trc mix (matured for 1 and 20 hours) and IC50 and MIC values of formulated Trc mix are 
summarised in the supplementary tables S1 to S4. From the Unpaired student t-test of fresh 
versus matured preparation pairs indicated that there were significant differences for the Trc 
mix alone as well as some of the 1:1 and 1:2 (m/m) formulations, showing that the 
formulation ratio and time have an influence on the activity (Table S1 and S2). When all the 
datasets were compared using One-way Anova with Bonferroni correlation test, we found 
fewer differences as this statistical method considers all the variability over this large dataset 
(Tables S3 and S4). This, however, indicated that the activity of Trc mix was preserved in 
these formulations. 
At specific ratios of formulated Trc mix in the cellulose derivatives, we observed significantly 
smaller IC50 values and/or MIC values (Table 3.4, Tables S1-S4). Depending on the 
concentration and the ratio, the cellulose derivatives enhance or support the activity of the 
Trc mix. From this E4M and E10M was revealed as two of the best formulants of Trc mix. 
MIC and IC50 values of formulated Trc mix by E10M at 1:1 and 1:4 ratios and E4M at 1:1 
and 1:2 ratios were consistently lower than 10 g/mL regardless of the maturation time. 
Matured Trc mix (20 hours of maturation) had statistically lower IC50 and MIC values than 
fresh Trc mix preparations (1 hour of maturation) (Table 3.4, Tables S1 and S2). Longer 
maturation of the preparations was observed to generally enhance the activity of the Trc mix 









IC50 and MIC values 
Table 3.4. Comparative activity data of formulated Trc mix targeting C. albicans and C. 
glabrata, Bar-graphs show the IC50 and MIC in µg/mL against C. albicans and C. glabrata. Errors 
bars represent SEM for a minimum of three biological and six technical repeats. The average MIC 
and IC50 in µg/mL are shown above each bar. Refer to tables S1-4 for details and statistical 
comparisons. 
1-hour maturation 
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Comparison of IC50 and MIC values 
target 
20-hours maturation 











































































































































































































































































































































3.4.3 The effect of cellulose derivatives on Trc mix anti-C. glabrata 
activity 
The four most promising formulations were also tested against a second Candida specie, 
namely C. glabrata at the same cell density as C. albicans. In general, MIC and IC50 values 
of 20-hour matured Trc mix preparations against C. glabrata were statistically higher than C. 





















Trc mix-formulant target 
 
   Comparison of the IC50 µg/mL against C. albicans and C. glabrata of 20 hour matured 
preparations (1:4 ratio). Data represent the mean of 3 biological repeats and 6-14 
technical repeats with SEM. Unpaired Student t-test was done on each of the analysed 
groups, with ** P<0.01 and ***P<0.001. 
 
Trc mix and Trc mix formulated with A4M and E10M had significantly smaller IC50 values 
when targeting C. albicans, than IC50 values against C. glabrata. As different target cells have 
different growth rates, differences in MIC or IC50 values are to be expected. Interestingly, the 
activity of K15M and E4M preparations of the Trc mix was observed to be similar against the 
two strains of Candida. This is an indication that the formulation modulated the activity to a 
point that different growth or different organisms had a minor influence. 
 
3.3.4 The effect of cellulose derivatives on Trc mix haemolytic activity 
When we considered the haemolytic activity of the different formulations, there was no clear 
distinction between the different formulations. All of the 1:4 (m/m) formulations showed similar 

























with the cellulose derivatives had a minor impact on the selectivity towards the erythrocyte 
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 Comparison of the haemolytic activity against human erythrocytes of the 20 hours matured 
1:4 Trc mix formulations. Data represent the mean of three biological repeats with SEM. 
Data is courtesy of W van Rensburg (Stellenbosch University). 
 
 
3.3.5 Anti-Candida of purified TrcA and TpcC and their formulations 
After testing the biological activity of different preparations of Trc mix, we investigated the anti-
Candida activity of purified TrcA and TpcC. (Refer to chapter two for purification and isolation 
of Trcs single analogue). 
Due to the time constraints and limited access to laboratory facilities during CoVID-19 
lockdown, the focus was only on these two peptides and two cellulose formulants, A4M and 
E4M. 
We chose one of the most hydrophobic (TrcA) and one of the most polar Trcs analogue 
(TpcC) to see whether formulation can improve the activity of these two analogues. As the 
hydrophobicity of the peptide depends on the identity of aromatic residues at positions 3, 4, 
and 7, TrcA containing two Phe is one of the most hydrophobic Trcs analogues, while TpcC 
containing three Trp is one of the most hydrophilic analogues. Previous research illustrated 
that Both TrcA and TpcC exhibit high activity against Aspergillus fumigates in addition to C. 
albicans 1, 13. 
Therefore, the anti-Candida activity of TrcA and TpcC was determined and compared with 
that of Trc mix, and standard anti-fungal drugs available on market, the antifungal lipopeptide 
Trc mix:Formulants 
























caspofungin (an echinocandin 14) and an antifungal azole, fluconazole 15. The activity 
parameters are summarised in Table 3.5. 
Table 3.5 Summary of the IC50 and MIC values of different preparations of the purified, peptides, 
selected formulations and two antifungal drugs against C. albicans. The n in brackets indicates the 
number of full dose responses. 
   IC50±SEM µM (n)  MIC±SEM µM (n) 
Formulant 
(Ratio, m/m) 
Peptide  or 
compound 
Fresh,  






20 hours  
1.5% EtOH Trc mix 7.9±0.6(12) 4.0±0.2(12) 11.3±1.1 (12) 5.6±0.3 (12) 
A4M (1:4) Trc mix 7.2±0.9(12) 5.9±0.6(12) 11.2±1.2 (12) 6.6±0.6 (12) 
E4M (1:4) Trc mix 6.6±0.9(12) 6.3±0.8(12) 9.4±1.4(12) 7.7±1.3(12) 
1.5% EtOH TrcA 3.9±0.3 (9) 4.4±0.2 (17) 6.1±0.6 (9) 7.3±0.6 (17) 
A4M (1:4) TrcA nd 5.4±0.5 (7) 7.8±0.0 (6) 7.0±0.7 (14)  
E4M (1:4) TrcA nd 5.5±0.6 (5) 5±0.6 (6) 8.90±0.8 (5)  
1.5% EtOH TpcC nd 10±1.1 (7) 22±3.2 (6) 22±2.7 (14) 
A4M (1:4) TpcC nd 9.8±1.4 (4) 20±3.8 (4) 19.3±3.5 (9) 
water Caspofungin nd nd >45.7 (6)  nd 
water Fluconazole nd nd >326.5 (6) nd 
The concentration of the peptides from Trc mix was calculated from the average Mr of 1318 for 
the peptide complex as calculated from the peptide contribution in the Trc mix determined in 
Chapter 2.   
 
TrcA has significantly lower IC50 and MIC values when compared to TpcC indicating a better 
overall antifungal activity of TrcA towards this environmental strain of C. albicans (refer to 
Table S5 in supplementary data). This correlates with results obtained by Troskie et al. 1. The 
difference between the anti-Candida activities of the two analogues can be due to their 
difference in hydrophobicity, or that TrcA forms more active higher oligomers compared to 
TpcC. Furthermore, the difference in the activity of these two analogues can be due to the 
difference in the peptide sequence and structure. The fact that TrcA has two Phe residues in 
positions 3 and 4 instead of two larger and more polar Trp residues may result in higher 
activity. It has been shown that Phe has a higher affinity for lipid membranes and inserts itself 
deeper that Trp into target cell membranes 17, 18. 
The anti-Candida activity of Trc mix and the purified TrcA and TpcC and selected formulations 
were compared with two antifungal drugs used in treatment for C. albicans, namely 
fluconazole and caspofungin (Table 3.5 and Figure 3.5). It is concerning that the Candida 
strain used in this study is fully resistant to fluconazole and resistant to caspofungin. Based on 
reported antifungal susceptibility testing of yeasts from standard clinical laboratories, MICs 
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higher than 64 and 2 µg/mL for fluconazole and caspofungin are considered resistant 19. 
(Table 3.5). However, it is highly susceptible to TrcA and Trc mix. Fluconazole, caspofungin 
and the less active TpcC resulted in the induction of metabolic stress in the Candida cells as is 
illustrated in Figure 3.5. Resazurin is an oxidation-reduction (REDOX) indicator dye that 
undergoes a colorimetric change in response to cellular metabolic reduction 19. Resazurin is a 
blue dye with low fluorescence and its reduced form, resorufin, is pink with high fluorescence 
19. The high conversion of resazurin to resorufin is associated with either cellular vitality or 
cellular stress response (Figure 3.5). 
 
Figure 3.5 Comparative activity data of different anti-fungal compounds targeting C. albicans. The 
pink/white and blue panels are representative of metabolically stressed and inactive of dead 
Candida cells, respectively. Errors bars represent SEM for a minimum of three biological and six 
technical repeats. The concentration in g/mL is presented as scaled filled circles (scale bar 
indicated on left). 
This is observed as “negative” metabolic inhibition, indicated as pink (colour of reduced dye) 
in Figure 3.5. When Candida cells are more stressed, they reduce resazurin faster and can 
result in the further bleaching of the dye due to further conversion of resazurin to resorufin 20. 
Upon induction of such stress signals, Candida cells can start to form biofilms 21 or they 
express multidrug-resistant (MDR) pumps to keep the anti-fungal compound out of the  
cells 22. These rapid adaptations and the fact that the yeast target is eukaryotic make the 
treatment of Candida infections especially difficult. However, TrcA and Trc mix did not result in 
an increase in metabolic stress. This means that there is a significantly smaller chance that 
Candida cells develop a resistance mechanism against these peptides due to rapid and 
multiple modes of action of Trcs. 
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For the formulation of the purified peptides, two of the promising cellulose derivatives were 
initially chosen namely A4M and E4M and formulations were prepared at peptide: cellulose 
derivatives 1:4 (m/m) matured over 1 and 20 hours. Both Trc A and TpcC were first formulated 
with A4M in a 1:4 (m/m) ratio. Neither the A4M formulated TpcC or TrcA exhibited better 
activity than the peptides alone after 1 hour or 20 hours of maturation (Table 3.5). TrcA 
maintained activity in E4M, but some activity was lost in A4M at 1-hour maturation. TpcC 
activity was also similar alone and in formulation (Table S5). This indicated preservation of 
the antifungal activity for TpcC and A4M. The activity of TrcA was preserved in E4M, but not 
stabilised over time (Table 3.5). TrcA showed a significant loss of activity in the A4M 
formulation, but this activity was preserved over time (Table S5). Increasing hydrophobicity 
of Trcs would result in the formation of bigger self-assembly/oligomers structures 6 and could 
lead to change in the activity. Therefore, if the dimers proposed by Loll et al. 7 and Munyuki 
et al. 8 are the active moieties, the Trc activity would be dependent on a critical 
concentration of oligomerisation. Oligomers in solution have to be in a certain size range for 
the optimum availability of dimers and activity. In the case of the more hydrophobic TrcA 
seems there may have been a minor disturbance of the oligomer population is a solution by 
A4M leading to the higher MIC values. Alternatively, it could be that active groups in the TrcA 




The biological activity of tyrocidines is highly dependent on the oligomerisation profile and the 
amphipathicity of the molecule 2, 3. However, Candida cells exposed to low concentrations of 
Trc mix, where less oligomerisation is expected, had an enhanced metabolic activity which 
resulted in the bleaching of the resazurin dye. These cells experience a substantial increase 
in aerobic metabolism and redox potential that could be an indication of cellular stress. These 
metabolically stressed cells could signal and induce Candida persister cells. Persister cells 
tend to form biofilms which makes it difficult for the antimicrobial agent to reach the target 20. 
These cells could survive while the Trc peptides kill the normal Candia population. 
It is hypothesised, that the oligomerisation profile of Trc mix is dynamic and peptide arranges 
and rearranges until it gets into the most favoured oligomer conformations and therefore in the 
ideal formulation, longer maturation (20 hours) resulted in oligomers that supported the 
release of dimer or more dimer in solution and therefore enhanced activity. Furthermore, we 
found that the formulation of Trc mix by cellulose derivatives and longer maturation of 
formulation components resulted in better activity, including the inhibition of potential persister
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cell induction. The biological activity of Trc mix was therefore successfully enhanced through 
formulation with more viscous cellulose derivatives. Among seven different cellulose 
derivative formulants of Trc mix utilised in this study, Trc mix formulated with E10M at 1:4 
(m/m) had significantly enhanced activity when targeting C. albicans and a minor 
enhancement in selectivity from 2- to 3-fold (results not shown). On the other hand, none of 
the formulations proved to be more selective, namely presenting reduced haemolytic activity. 
In contrast, pure TrcA or TpcC did not follow that same activity behaviour as Trc mix when 
matured longer. This could be that TrcA has a relatively stable oligomer population in solution 
because of its hydrophobicity, therefore, longer maturation does not result in a major change 
in oligomerisation and biological activity. TpcC is more polar but parallel studies by our  
group 22 showed that it formed large oligomers. Again, prolonged maturation did not result in 
enhanced activity, probably because this peptide is inherently less active or that the 
formulants are unable to modulate the oligomerisation to improve activity.   This is in contrast 
to Trc mix which contains a complex mixture of different analogues, including TrcA and a 
small amount of TpcC. It is possibly that longer incubation is needed to form stable homo- 
oligomers and hetero-oligomers that has high activity towards Candida cells. It is 
hypothesised that the formulation of Trc mix by cellulose derivatives causes a conformational 
change of the oligomeric structures. The rearrangement of oligomers in the formulation form 
more active structures from which the proposed active amphipathic dimers 8 can be released 
or that more dimers remain in solution for interacting with the Candida target cell wall and 
membrane. It can be concluded that the formulation of Trc mix was successful as they 
enhanced the biological activity of Trc mix over time which indicated the increased stability of 
the active moieties in the formulations. This hypothesis will be further explored in chapter 4 
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3.7. Supplementary data 
 
Table S1 Summary of the IC50 and MIC values of different preparations of Trc mix against C. albicans. 
 
IC50±SEM in µg/mL MIC±SEM in µg/mL 
 
Control - (n=34)10.5±0.8 (n=20)5.3±0.3 (n=34)14.9±1.5 7.5±0.5 
A4M 1:1 (n=20)8.7±1.4 (n=12)4.6±0.3 (n=2014.0±2.4 (n=12)6.7±0.5 
E4M 1:1 (n=20)7.1±1.1 (n=12)5.3±0.4 (n=2013.7±2.5 (n=12)7.2±0.7 
E10M 1:1 (n=16)7.4±1.1 (n=12)5.6±0.5 (n=16)12.5±1.7 (n=12)9.8±0.9 
K15M 1:1 (n=16)8.9±1.0 (n=12)6.3±1.2 (n=16)12.8±1.6 (n=12)13.0±1.2 
A4M 1:2 (n=16)8.9±0.6 (n=12)4.8±0.1 (n=16)12.1±0.1 (n=12)7.2±0.7 
E4M 1:2 (n=16)10.3±0.7 (n=12)5.6±1.1 (n=16)14.8±1.2 (n=12)6.2±0.7 
E10M 1:2 (n=16)9.1±0.3 (n=12)6.2±0.5 (n=16)12.1±0.3 (n=12)13.5±1.0 
K15M 1:2 (n=16)8.9±0.9 (n=12)5.1±0.2 (n=16)11.3±0.6 (n=12)7.8±0.8 
A4M 1:4 (n=16)9.5±1.3 (n=12)7.8±0.8 (n=16)14.8±1.6 (n=12)8.8±0.9 
E4M 1:4 (n=16)8.8±1.3 (n=12)8.4±1.1 (n=16)12.5±1.9 (n=12)10.2±1.7 
E10M 1:4 (n=16)6.4±0.5 (n=12)3.2±1.0 (n=16)10.1±1.2 (n=12)4.6±0.8 
K15M 1:4 (n=16)8.2±1.3 (n=12)7.7±1.08 (n=16)12.4±1.9 (n=12)11.0±1.8 
 
 
Table S2 Statistical comparison of IC50 between different Trc mix of fresh (1 hour) and matured (20 
hours) formulations. The analysed IC50 and MIC values represent the mean of 3-4 biological repeats 
and 12-32 technical repeats with SEM. Unpaired Student t-test was done on each of the analysed 
pairs and only those with significant differences are shown. 
Formulant 1 Formulant 2 
IC50 ± SEM 
(µg/mL) 1 
IC50± SEM (µg/mL) 2 P value 
Control 1h matured Control 20h matured 10.5±0.8 5.3±0.3 <0.0001 
Tmix E4M (1:2) 1h 
matured 
Tmix E4M (1:2) 20h 
matured 
10.3±0.7 5.6±1.1 <0.0001 
Tmix E10M (1:2) 1h 
matured 
Tmix E10M (1:2) 20h 
matured 
9.1±0.3 6.2±0.5 <0.0001 
Tmix E10M (1:4) 1h 
matured 
Tmix E10M (1:4) 20h 
matured 
6.4±0.5 3.2±1.0 0.0021 
Tmix K15M (1:2) 1h 
matured 
Tmix K15M (1:2) 20h 
matured 
8.9±0.9 5.1±0.2 0.0017 
Formulant 1 Formulant 2 
MIC ± SEM 
(µg/mL) 1 
MIC± SEM (µg/mL) 2 P value 
Control 1h matured Control 20h matured 14.9±1.5 7.5±0.5 0.007 
Tmix A4M (1:1) 1h 
matured 
Tmix A4M (1:1) 20h 
matured 
14.0±2.4 6.7±0.5 0.0203 
Tmix A4M (1:4) 1h 
matured 
Tmix A4M (1:4) 20h 
matured 
14.8±1.6 8.8±0.9 0.0065 
Tmix E10M (1:4) 1h 
matured 
Tmix E10M (1:4) 20h 
matured 















Table S3 Statistical comparison of IC50 between different formulations of Trc mix. The IC50 values 
analysed were the mean of 3-4 biological repeats and 12-32 technical repeats with SEM. One way 
Anova with Bonferroni correlation test was done between each of the selected data sets groups 
 
 20 hours of maturation 
 1:4 1:2 1:1  




















K15M ns <0.05 ns ns ns ns ns ns ns ns ns ns ns 
E10M ns <0.05 ns ns ns ns ns ns ns ns ns ns ns 
E4M ns <0.05 ns ns ns ns ns ns ns ns ns ns ns 




K15M ns <0.05 ns ns <0.01 ns ns ns ns ns ns ns ns 
E10M ns <0.01 ns ns ns 0.001 ns ns ns <0.01 ns ns ns 
E4M ns 0.001 ns ns ns ns <0.01 <0.05 ns ns <0.05 <0.05 ns 




K15M ns <0.05 ns ns <0.05 ns ns ns ns ns ns ns ns 
E10M ns 0.001 ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns ns ns ns 
A4M ns <0.01 ns ns ns ns ns <0.05 ns ns ns <0.05 ns 
 Control ns 0.001 <0.05 <0.05 <0.01 <0.05 <0.05 <0.01 ns <0.05 0.001 0.001 0.001 
 1 hour of maturation 
 1:4 1:2 1:1  


























K15M ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns ns ns ns ns ns ns ns <0.01 
E4M ns ns ns ns ns ns ns ns ns ns 
A4M  ns ns ns ns ns ns ns ns ns 
K15M      ns ns ns ns ns ns ns ns 
E10M       ns ns ns ns ns ns ns 
E4M        ns ns ns ns ns ns 
A4M         ns ns ns ns ns 
K15M          ns ns ns ns 
E10M           ns ns <0.05 
E4M            ns ns 
A4M             ns 
 20 hours of maturation 
 1:4 1:2 1:1  



























K15M ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns 0.001 ns ns ns 0.001 ns ns <0.01 
E4M ns ns ns ns ns ns ns ns ns ns 
A4M  ns ns ns ns ns ns ns ns ns 
K15M      ns ns ns ns ns ns ns ns 
E10M       ns ns ns ns ns ns ns 
E4M        ns ns ns ns ns ns 
A4M         ns ns ns ns ns 
K15M          ns ns ns ns 
E10M           ns ns ns 
E4M            ns <0.05 
A4M             ns 
Stellenbosch University https://scholar.sun.ac.za
3-23  
Table S4 Statistical comparison of determined MICs against C. albicans between different formulations of Trc 
mix. The MIC values analysed were the mean of 3-4 biological repeats and 12-32 technical repeats with SEM. 
One-way Anova with Bonferroni correlation test was done between each of the selected data sets groups. 
 
 20 hours of maturation 
 1:4 1:2 1:1  




















K15M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns ns ns ns 




K15M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns <0.05 ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns <0.05 ns ns 




K15M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns <0.01 ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns <0.05 ns ns 
A4M ns ns ns <0.05 ns ns ns ns ns ns 0.001 0.001 0.001 
 Control ns ns ns <0.05 ns ns ns <0.05 ns ns ns <0.01 0.001 
 1 hour of maturation 
 1:4 1:2 1:1  




















K15M ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns 




K15M      ns ns ns ns ns ns ns ns 
E10M       ns ns ns ns ns ns ns 
E4M        ns ns ns ns ns ns 




K15M          ns ns ns ns 
E10M           ns ns ns 
E4M            ns ns 
A4M             ns 
 20 hours of maturation 
 1:4 1:2 1:1  





















K15M ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns <0.01 ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns 




K15M      ns ns ns ns ns ns ns ns 
E10M       ns ns ns ns ns ns ns 
E4M        ns ns ns ns ns ns 




K15M          ns ns ns ns 
E10M           ns ns ns 
E4M            ns ns 
A4M             ns 
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Table S5 Statistical comparison of MIC values between different formulations of TrcA and TpcC. One-way 
Anova with Bonferroni correlation test was done between each of the selected data sets groups. 
  20 hours of maturation 
















Peptide Formulant Control A4M E4M Control A4M 
TrcA 
Control ns ns ns 0.001 0.001 
A4M ns ns ns <0.01 0.001 
E4M ns ns ns 0.001 0.001 
TpcC 
Control 0.001 0.001 0.001 ns ns 
A4M 0.001 0.001 0.001 ns ns 
  1 hour of maturation 
















Peptide Formulant Control A4M E4M Control A4M 
TrcA 
Control ns ns ns 0.001 0.001 
A4M ns ns ns 0.001 <0.01 
E4M ns ns ns 0.001 0.001 
TpcC 
Control 0.001 0.001 0.001 ns ns 
A4M ns ns ns ns ns 
  20 hours of maturation 

















Peptide Formulant Control A4M E4M Control A4M 
TrcA 
Control ns ns ns ns ns 
A4M ns ns ns ns ns 
E4M ns ns ns ns ns 
TpcC 
Control 0.001 0.001 0.001 ns ns 









During the purification and isolation of Trc mix single analogues reported in Chapter 2, we 
observed the known oligomerisation of the peptides 1, 2, 3. It was hypothesised that the 
peptides in Trc mix interact with glucose moieties in polysaccharides, as previously found 
by Juhl et al 4. In Chapter 3 the formulation of Trc mix with polysaccharides led to changes 
in activity against C. albicans and human erythrocytes. It was shown that Trc mix 
formulations containing certain cellulose derivatives have an enhanced anti-Candida 
activity. Furthermore, we found that 20 hours matured Trc mix-cellulose derivative 
preparations are significantly more active against Candida species. Considering the 
tendency of the peptides to oligomerise, we decided to investigate the interaction of the 
aromatic amino acid residues in Trc mix with cellulose derivatives and their influence on the 
fluorescence properties of the Trcs. 
Most of the dimeric structures that were found by Munyuki et al. 5 and Loll et al. 6 via 
modelling studies, retain their amphipathic properties allowing for the interaction of the 
peptide and the target cell membrane and therefore, destabilising of the membrane. it is 
proposed that the dimeric peptide is the bioactive structure. Therefore, it was hypothesised 
that the presence of specific functional groups on cellulose moieties may weaken the 
interaction between the peptide molecules to limit the formation of larger peptide oligomers 
that form over 20 hours of maturation. In this, the formulation could support oligomer 
conformation(s) that allows the release of membrane-active dimers and other oligomers or 
aid the solution retention. This chapter reports the influence of maturation and cellulose 
derivatives on biophysical properties of the Trc mix. We aimed to monitor and compare the 
formation of self-assembly structures of Trc mix and formulated Trc mix by cellulose 
derivatives after 1, 4 and 20 hours of maturation. Formulants, identical to those used in the 
activity studies against Candida species, were used, namely soluble celluloses with different 
cellulose derivatives containing methyl, ethyl, propyl, and hydroxyl side chains resulting in 
varying hydrophobicity of the formulant (Figure 4.1A and B). 
The presence of 4/10 aromatic amino acids such as Trp, Tyr and Phe in the structure of the 


































       Examples of cellulose derivatives and Trcs studied in this chapter with A. chitosan 
polymer, B. core of hydroxyl and methylcellulose derivatives, and C. primary structure of Trc C 
indicating the four aromatic amino acids in the cyclic peptide structure. 
 
Rigid chromophores such as aromatic amino acids (Trp, Tyr and Phe) have a limited range 
of vibrational energy level 7. When these chromophores absorb light, they will return to the 
ground estate by emitting photons. This phenomenon is called fluorescence and such 
molecules are called fluorophores 7. Fluorescence is the result of a three-state electronic 
transition namely, excitation (light absorption), excited estate lifetime (an extremely short 
time in which fluorophore stays in the excited state), emission (release of the photon by the 
fluorophore and returning to the ground state) 7 (Figure 4.2). As some of the light absorbed is 
always lost during the transition from the excited to the emitted state, the emitted spectrum 
lies at a lower energy level/longer wavelength than the excited spectrum8. Furthermore, 
the emitted spectrum can be quenched due to two other processes namely: internal and 
external quenching 7, 8, 9. Internal quenching/self-quenching is due to some intrinsic 
features of the excited molecules such as the tendency of the molecule for structural 
rearrangement or oligomerisation/aggregation. External quenching arises when another
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molecule present in the sample (polar solvent) absorbs the emitted energy. All forms of 
quenching results in non-radiative energy emission. However, if a fluorescent molecule is 
excited into a more polar environment (e.g., a high concentration of cellulose derivatives), 
the solvent molecules immediately adjust to the electron distribution in the fluorophore. The 
adjustment of the solvent molecules with the excited fluorescent molecule’s electron 
distribution does not happen instantaneously thus the solvent molecules react using 
dielectric relaxation until the corresponding excited state is reached. The same process 
occurs during emission, which results in the fluorescent spectrum experiencing a red shift. 
If a molecule is excited into a less polar environment, the emitted fluorescent spectrum 
experiencing a blueshift 7, 8, 9, 10, 11, 12. 
Fluorescence spectrometry is generally utilised in biophysical and biochemical studies of 
peptides and proteins as the frequency in which the light is absorbed is affected by the 
environment and the structure of the molecules. Therefore, the influence of the environment 
on the fluorophore, the components of a solvent, and the molecular interaction/stability can 
be identified via fluorescence spectrometry. Furthermore, as this technique is highly 
sensitive there is only a small quantity of the sample needed 7, 8, 9, 10. 
As mentioned before, aromatic amino acids are good fluorophores, due to their absorbing 
aromatic ring structures and high resonance energy. Trp is the best fluorophore of the 
aromatic amino acid residue with ʎ excitation at 282 nm and ʎ emission at 348 nm 9. Trp is highly 
solvatochromic, meaning, the fluorescence of Trp is influenced by the environment (solution) 
and the proximity of other protonated groups of nearby residues as these can cause 
fluorescence quenching 7, 9. Therefore, the nearby charged amino acid groups can transfer 
electrons from protonated carboxyl groups, electron transfer can occur by peptides bonds, 
and electrons can be accepted by the formulation components. All of these can then lead to 
the fluorescence signal quenching 9, 11, 12. 
Tyr with ʎ excitation is at 267 nm and ʎ emission at 350-303 nm is the second-best fluorophore in 
proteins and the tyrocidines. The emitted spectrum is quenched in a polar environment. 
Furthermore, Tyr fluorescence has been observed to be quenched by the presence of 
nearby tryptophan moieties via resonance energy transfer 9. Phe is a weak fluorophore with 
ʎ excitation at 256 nm and ʎ emission at 282 nm 9. Its emitted spectrum can be only observed in 
the absence of both Trp and Tyr. Trp is, therefore, a major fluorophore in the tyrocidines and 
tryptocidines as it has greater resonance energy transfer, absorptivity and higher 
quantum yield compared to Tyr and 
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Phe 9, hence chosen as the main fluorophore for the biophysical studies reported in this 
chapter. 
 
     Physical basis of fluorescence. As aromatic amino acid residues are rigid molecules 
with few vibrational levels (four levels are shown in this scheme) the released energy 
from the excited estate to the ground estate is in form of a photon 7. 
To assess the formulant stability-activity relationships, the Trp fluorescence was utilised, as 
many of the cyclodecapeptides in Trc mix contain Trp such as Trc B, B1, C and C1 with minor 
contribution by TpcA, A1, B, B1, C and C1. Trp fluorescence would allow the monitoring of 
localised changes in oligomerisation of the peptide in the Trc mix and formulations. 
 
4.2 Materials 
TpcC was purified from Brevibacillus parabrevis culture extracts (refer to chapter two for 
more details). Commercial tyrothricin extract was supplied by Sigma-Aldrich (St Louis, USA). 
Ethanol, diethyl ether and acetone were supplied by Merck (Darmstadt, Germany). 
Analytical grade water (MQH2O) was prepared by filtering water from a reverse osmosis 
plant through a Millipore-Q® water purification system (Milford. USA). The 96-well black and 
transparent flat-bottom plates were supplied by Thermo Fisher Scientific (Denmark). 
Benecel A4M(A4M), Benecel E4M (E4M), Benecel E10M (E10M), Benecel K15M (K15M) 
Klucel E IND (KLUE). Klucel L IND (KLUL) were donated by ASHLAND, Covington, 
Kentucky America. Chitosan was purchased from Sigma-Aldrich (St Louis. USA). Tyrocidine 
mixture (Trc mix) was extracted from commercial tyrothricin using diethyl ether and acetone 
13 (also refer to Chapter 2 for details on the Trc mix preparation) 
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4.3.1 Fluorescence spectroscopy 
To determine the biophysical characteristics of formulated Trc mix, formulants were 
prepared as described before (chapter three) in 15% ethanol (v/v) followed by a 10-fold 
dilution by adding 90 µL of filter-sterilized MQH2O. The Trc mix formulation preparation and 
analysis parameters are summarised in Table 4.1. 
       Summary of the composition and the preparation of different formulation of Trc mix 







1, 4, 20 
ratio (m/m) 
- 






A4M 1, 4, 20 1:1 50 280, 320-400 
E4M 1, 4, 20 1:1 50 280, 320-400 
E10M 1, 4, 20 1:1 50 280, 320-400 
KLUE 1, 4, 20 1:1 50 280, 320-400 
KLUI 1, 4, 20 1:1 50 280, 320-400 
CHS 1, 4, 20 1:1 50 280, 320-400 
K15M 1, 4, 20 1:1 50 280, 320-400 
A4M 1, 4, 20 1:2 50 280, 320-400 
E4M 1, 4, 20 1:2 50 280, 320-400 
E10M 1, 4, 20 1:2 50 280, 320-400 
K15M 1, 4, 20 1:2 50 280, 320-400 
A4M 1, 4, 20 1:4 25,50 280, 320-400 
E4M 1, 4, 20 1:4 25,50 280, 320-400 
E10M 1, 4, 20 1:4 25,50 280, 320-400 
K15M 1, 4, 20 1:4 25,50 280, 320-400 
Control* Continual 60 minutes 1:4 100-1.25 280, 340 
A4M Continual 60 minutes 1:4 100-1.25 280, 340 
E4M Continual 60 minutes 1:4 100-1.25 280, 340 
Control* Continual 60 minutes 1:4 50 280, 320-400 
A4M Continual 60 minutes 1:4 50 280, 320-400 
E4M Continual 60 minutes 1:4 50 280, 320-400 
* 1.5% Ethanol in MQH2O (v/v) 
In all assays, the excitation wavelength was 280 nm. However, the emission parameters 
differed between different assays. For assays with 50 µg/mL Trc mix, fluorescence emission 
was scanned from 320 nm to 400 nm, while for assays with the titrated concentrations of 
Trc mix (ranging from 100 to 1.2 µg/mL), fluorescence emission was measured at 340 nm. 
The emission bandwidth was 20 nm with 10 flashes and Z position of 2000 µm. All 
fluorescence readings were collected using the Tecan Spark 10M Multimode Microplate 
Reader. Readings were taken after 1, 4 and 20 hours of maturation. Continuous readings 
over 60 minutes were taken for titrated Trc mix and formulated Trc mix with A4M and E4M. 
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Readings were taken with six to twelve repeats to allow the statistical comparison of the 
preparations. 
The titrated concentration of TpcC (95% purity), ranging from (1000 to 30 µM) were prepared 
as described before in 20% acetonitrile (v/v) followed by a 10 times dilution by adding 90 µl 
of 20% acetonitrile (v/v). Readings were taken continuously for 60 minutes. The excitation 
wavelength was 280 nm and emission 340 nm. The emission bandwidth was 20 nm with 10 
flashes and Z position of 2000 µm. All fluorescence readings were collected every two 
minutes, using the Tecan Spark 10M Multimode Microplate Reader. Readings were taken 
with three technical repeats to minimise the possible technical errors. 
 
4.4 Results and discussion 
 
4.4.1 Fluorescence spectrometry of Trc mix and its formulations 
Various non-covalent and hydrophobic interactions play important roles in the formation of 
higher/larger oligomers. The presence of four aromatic amino acid residues and three 
hydrophobic residues in tyrocidines would drive hydrophobic interactions in aqueous 
systems between the peptides to form oligomers that may lead the change in their optical 
characters such as a change in absorption and fluorescence emission. Trcs have three 
aromatic fluorophores namely Phe, Tyr and Trp. As mentioned, Trp was chosen for this 
study as a fluorophore as it is a major fluorophore with greater resonance energy transfer, 
absorptivity and higher quantum yield 9. 
Trc mix at 50 µg/mL in 1.5% ethanol: analytical grade water (v/v) was used as control. The 
formulation stability, when combined with six different cellulose derivatives and chitosan 1:1 
(m/m), was studied utilising fluorescence spectrometry. The concentration of 50 µg/mL Trc 
mix was chosen as the Candida cultures treated with the different Trc mix formulations 
showed 100% metabolic inhibition at this concentration. The Trp fluorescence was 
considered as the major contributor to the detected fluorescence emission between 320- 
400 nm, which was determined after 1, 4 and 20 hours of maturation. The change in total 
fluorescence of formulated Trc mix at the three time points of maturation is shown in Figure 
4.3. Each preparation was monitored individually as technical repeats may not have identical 
behaviour due to the sensitivity of the Trc oligomerisation to the plastic surface 
contact 14, the time during pipetting, time after mixing, the sequence of adding components 
and small temperature variations. The formation of unstable oligomers and dynamic 
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changes in oligomerisation can therefore be monitored and compared by assessing the 
scattering of data points (Figure 4.3). 
For all the preparations, the fluorescence scattering of Trc mix formulations increased 
dramatically from 1 to 4 hours. This then remained relatively stable for all the preparations 
except for the control in 1.5% ethanol: water (v/v) and formulation with A4M that both 
exhibited increased scattering at 20 hours (Figure 4.3C). The other formulations of Trc mix 
showed less scatter after an hour of incubation and after 20 hours when compared to the 
control, considering a scatter parameter that was defined as: Average of 12 
repeats/standard deviation = signal/noise = S/N. This was discussed in more detail below in 
the discussion on a global comparison of all the datasets (refer to Figure 4.6B in discussion 
below). This stabilisation of fluorescence can be contributed to the interaction of cellulose 
derivatives and Trc mix which prevents/slows down the formation and dynamic 
rearrangement of oligomers. However, the concentration of cellulose derivatives at 50 
µg/mL may not fully stabilise all the Trc molecules at 50 µg/mL and they still 
aggregate/oligomerise over 20 hours resulting in a larger scattering. The 
aggregation/oligomerisation is supported by the lower total fluorescence or quenching for all 
twelve technical repeats at 20 hours versus 1 hour of maturation (Figure 4.3, refer to Figure 
4.6 in discussion below). The lower quantum yield of Trp could be due to either the exposure 
of the Trp residue to the polar solvent, polar groups in the celluloses, interaction with polar 
groups 7 (Lys, Orn, Gln, Asn and Tyr side chains) and/or due to aromatic stacking 7, 9. 
Comparing the mean of percentage fluorescence loss over 20 hours of maturation, Trc mix 
lost close to half the Trp signal intensity while formulated Trc mix lost about a third of the 
Trp signal intensity (Table 4.2). 
       Summary of %relative fluorescence unit (RFU) loss measured for each of the eight 
formulants of Trc mix 1:1 (m/m) from 1 to 4 and 1 to 20 hours of maturation. The 
relative loss is also indicated as a heat map with blue the lowest lost and red the 
highest loss. 
 
Mean of % RFU loss from 1 hour 
Cellulose 
derivatives 
4 hours of 
maturation 
20 hours of 
maturation 
Control 23 45 
A4M 22 32 
E4M 20 25 
E10M 24 31 
KLUE 19 26 
KLUI 22 30 
CHS 25 35 
















Control A4M E4M E10M KLUE KLUL CHS K15M 
 
Trc mix: formulant 1:1 (m/m) 
















Control A4M E4M E10M KLUE KLUL CHS K15M 
 
Trc mix: formulant 1:1 (m/m) 


















Control A4M E4M E10M KLUE KLUL CHS K15M 
 
Trc mix: formulant 1:1 (m/m) 
after 20 hours of maturation 
       Comparison of Trp total fluorescence in relative fluorescence units (RFUs) of the 50 
µg/mL Trc mix preparations after A.1, B. 4, and C.20 hours of maturation in solution with different 
cellulose derivatives at 1:1 (m/m) ratio. Twelve preparations of each formulation are shown with the 




























































The most stable formulations in terms of Trp fluorescence contained CHS and K15M, 
followed by KLUE and KLUL. Interestingly, CHS, KLUE and KLUL followed by E4M had very 
high S/N after one hour of maturation which significantly decreased over 20 hours of 
maturation (Figure 4.3, refer to Figure 4.6F). These four formulants have the lowest 
viscosity, which indicates that viscosity may be important in the time-dependent maturation 
and stabilisation. This result further indicates that cellulose derivatives do influence and 
possibly delay the formation of the large oligomers. However, it also seems that too much 
stabilisation or the low viscosity correlates with the weaker activity of the formulants against 
C. albicans as reported for CHS, KLUE and KLUL in Chapter 3. It is hypothesised that highly 
stable oligomers may not have a high enough affinity to bind to the cell membrane of the 
target organism, possibly because of the masking of active groups and/or thermodynamic 
stability of the formulant-peptide oligomers that traps the peptides. Therefore KLUE, KLUL 
and CHS were omitted from the rest of the biophysical studies. 
In the following studies, we considered the formulation of 50 g/mL Trc mix with increased 
concentrations at 100 µg/mL and 200 µg/mL of A4M, E4M, E10M and K15M to yield 
formulation ratios of 1:2 and 1:4, respectively (Figures 4.4 and 4.5). The Trp signal loss of 
formulated Trc mix by cellulose derivatives at 1:2 (m/m) ratio was less than formulations at 
1:1 (m/m) ratio further confirming the influence of cellulose derivatives on prevention/slowing 
down the formation of oligomers (Figure 4.4). The S/N ratios for all the 1:2 formulations were 
above 6 which is higher than control and Trc mix: cellulose derivatives at 1:1 (m/m) ratio, 
except for K15M at 1 hour (refer to Figure 4.6D). There was no significant increase in the 
scattering of the data as none of the preparation’s S/N ratio decreased, except for the 
control, at 20 hours of maturation (refer to Figure 4.6D). 
As 100 µg/mL of cellulose derivatives per 50 µg/mL Trc mix stabilised the Trp fluorescence 
over 20 hours of maturation, we increased the formulants concentration even further (200 
µg/mL per 50 µg/mL Trc mix) yielding a ratio of 1:4 (m/m) to investigate any other possible 
changes in Trp fluorescence over 20 hours of maturation (Figure 4.5 A-C). The 200 µg/mL 
of cellulose derivatives per 50 µg/mL Trc mix yielded stable formulations with much less 
scatter and the Trp fluorescence signal loss was significantly lower when compared to Trc 
mix by formulated 50 µg/mL of cellulose derivatives (refer to addendum Tables S1-S4 for 
statistical analyses). The S/N ratios for the 1:4 formulations are higher for all preparations 
compared to 100 µg/mL of cellulose derivatives and remains constant over 20 hours of 






















Control A4M E4M E10M K15M 
Trc mix: formulant 1:2 (m/m) 















Control A4M E4M E10M K15M 
Trc mix: formulant 1:2 (m/m) 

















A4M E4M E10M K15M 
Trc mix: formulants 1:2 (m/m) 
after 20 hours of incubation 
 
       Comparison of Trp total fluorescence in RFUs of the 50 µg/mL Trc mix preparations 
after A.1 hour, B. 4 hours, and C. 20 hours of maturation in solution with different cellulose 









































































Control A4M E4M E10M K15M 
Trc mix: formulant 1:4 (m/m) 
















Control A4M E4M E10M K15M 
Trc mix: formulant 1:4 (m/m) 


















A4M E4M E10M K15M 
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after 20 hours of maturation 
 
       Comparison of Trp total fluorescence in RFUs of the 50 µg/mL Trc mix preparations 
after A.1, B. 4, and C.20 hours of maturation in solution with different cellulose derivatives at 1:4 
















































































































































An increased ratio of cellulose derivatives resulted in the increased S/N ratio, signifying more 
stable formulations up to 20 hours (refer to Table 4.3 and Figure 4.6). As an example, 50 
and 100 µg/mL of K15M, had significantly different S/N after 1, 4 and 20 hours of maturation, 
but 200 µg/mL of K15M had a constant S/N over 20 hours with a 130% improvement in S/N 
for the 1:2 formulation (Figure 4.6D and Table 4.3). A comparative summary of the results 
is given in Figure 4.6 and Table 4.3. 
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       Comparison of the total fluorescence changes of formulated Trc mix at 50 µg/mL and 
different ratios of cellulose derivatives over time with A. 1:1 (m/m) ratio, C. 1:2 (m/m) ratio and E.1:4 
(m/m) ratio. Each bar represents the mean of 12 preparation and their determinations with SD. B, D 
and F show the S/N comparison of the respected datasets. The dotted lines show the comparison 





































































       Summary of %S/N loss, indicating instability, measured for each of the five formulants 
of Trc mix 1:1, 1:2 and 1:4 (m/m) from 1 to 20 hours of maturation. 
 
% loss of S/N over 20h of maturation 
 Trc mix: cellulose 
derivatives 1:1 (m/m) 
Trc mix: cellulose 
derivatives 1:2 (m/m) 
Trc mix: cellulose 
derivatives 1:4 (m/m) 
Control 39 39 39 
A4M 60 2 13 
E4M 55 11 11 
E10M 44 2 (gain) 7 
K15M 46 130 (gain) 7 
 
As seen in Figure 4.6, the Trc mix (control) lost close to half of the Trp fluorescence signal 
over 20 hours. This significant signal loss is mostly attributed to the stacking of the aromatic 
residue peptide molecules, specifically quenching of the Trp fluorescence (refer to tables S2-
4 in supplementary data). Upon addition of the cellulose derivatives to the Trc mix 
preparation at 50 µg/mL, the signal loss decreased significantly (Figure 4.6A and B, Table 
4.3, Table S1, refer to Tables S2-4 for statistical analyses). It is assumed that cellulose 
derivatives inhibit the aromatic stacking in oligomers resulting in less quenching of the total 
Trp signal. However, the concentration of the cellulose derivatives is too low in the 1:1 
formulants to form stable formulation therefore after 20 hours of maturation the signal loss 
can still be observed. In Figure 4.6 C, D and E, F it can be seen that the Trp signal 
fluorescence measured for Trc mix formulations at ratios of 1:2 and 1.4 are significantly 
more stable over 20 hours of maturation (refer to Tables S3 and S4 for statistical analyses). 
It is hypothesised that in addition to slowing down the formation of large oligomers, the 
higher concentration of the cellulose derivatives results in the formation of smaller and more 
stable oligomers over 20 hours maturation. The cellulose derivatives “interfere” with the 
stacking of aromatic amino acid residues, with the latter resulting in Trp fluorescence signal 
loss. This could happen via direct interaction with certain residues, specifically involving 
residues 4 and 9 (D-Trp4 or D-Phe4 and Orn9/Lys9) in the peptides as shown by Juhl et al. 4. 
Alternatively, the formulants may have a chaotropic effect in which oligomerisation via 
hydrogen bonding of the peptide molecules, form β-sheet type oligomers 5, 6, direct steric 
hindering of aromatic stacking or the hydrophobic forces are disrupted. The latter could be 
directly related to water preferentially interacting with the cellulose OH-groups (hydration of 
formulants). This effectively will lower the water activity reducing the hydrophobic clustering 
of the aromatic and hydrophobic groups. As these oligomers in the 1:2 and 1:4 formulations 
are possibly an optimal size and stability to remain in solution, they do not constantly 
rearrange resulting in a constant high S/N ratio over 20 hours of maturation (refer to Figure 
4.6 D and F). Therefore, it is concluded that increased concentration of cellulose derivatives
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results in a more stable Trp fluorescence meaning the solution conformation and oligomers 
of the peptides in the Trc mix were better stabilised. 
 
4.4.2 Effect of time and concentration on the formation of oligomers 
Maturation time had a major influence on the total Trp fluorescence signal observed for Trc 
mix and its formulations. To further investigate the conformational changes of the Trp- 
containing peptides in the Trc mix and formulated Trc mix fluorescence was monitored 
continuously over the first 60 minutes at 50 and 6.25 µg/mL Trc mix (Figure 4.7). Trc mix in 
the control solution (1.5% ethanol in analytical grade water. v/v) and in A4M (200 and 25 
µg/mL) showed a large Trp fluorescence loss in the first 6 minutes. This indicates a rapid 
change in the solution conformation/oligomerisation or rapid settling out of the solution. 
Visual inspection of the solutions did not reveal any opacity or over precipitation of the 
components. It was assumed that interaction with the surface will be similar to the % signal 
loss. Therefore, it was assumed that the major change in Trp fluorescence signal, is due to 
the conformational reorganisation of the peptide molecules (Figure 4.7). However, Trc mix 
(50 and 6.25 µg/mL) in E4M (200 and 25 µg/mL), did not show a rapid Trp fluorescence loss 
in the first six minutes (Figure 4.7E), which can be due to two reasons. First, the oligomers 
may have already formed before measuring started (the time from preparing the formulation 
until measuring the fluorescence) and second, that E4M stabilised the formation of the 
oligomers, therefore the rapid stacking of aromatic amino acids did not occur in the first six 
minutes of the maturation. 
The initial and final fluorescence observed of different preparations of 6.25 µg/mL Trc mix 
which were relatively similar, indicating similar changes in Trp environment at the low 
concentration of Trc mix and that the formulants did not have an influence. However, the 
observed initial and final fluorescence (fluorescence at 12 minutes and 60 minutes, 
respectively) of different preparations of 50 µg/mL Trc mix were very different from one 
another, with control having the highest and E4M having the lowest starting/ending 
fluorescence. This indicated that the Trp residues were in different environments in the three 
formulations with 50 µg/mL Trc mix. The Trp environment, in contrast with 6.25 µg/mL Trc 
mix, was both influenced by the formulant and concentration, indicating that concentration- 
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       Fluorescence emission spectra (excitation at 280 nm) over time with A. Trc mix at 
50 µg/mL in control solution, C formulated with 200 µg/mL A4M and E 200 µg/mL E4M and B Trc 
mix at 6.25 µg/mL D formulated with 200 µg/mL A4M and F 200 µg/mL E4M. Each data point is the 
mean of three replicates. 
By plotting the Trp fluorescence at 12-60 minutes for control and formulations with 50 and 
6.25 µg/mL of Trc mix, the ∆RFU/minute (∆RFU = change in relative fluorescence units) 
was calculated using the slope of Trp fluorescence decrease from 12-60 minutes and was 
attributed to the rate of the formation of oligomers at a certain concentration (Figure 4.8A 
and B). 
Although different formulations of Trc mix at the same concentration had the same 
aggregation/oligomerisation rate, this rate was different between 50 and 6.25 µg/mL of 
control and cellulose derivatives preparation of Trc mix. This result indicated that at the 
























































when compared to the lower concentration of 6.25 µg/mL Trc mix (Figure 4.8A). This 
confirmed that the Trc mix concentration was the main driver in fluorescence loss and that 
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Trc mix preparation 
       Monitoring the influence of the formulation on the aggregation rate of A. 50 µg/mL 
and B. 6.25 µg/mL Trc mix. The numbers on the graphs indicated the slope and 
aggregation/oligomerisation rates (∆RFU/minute) from 12-60 minutes. SD shows the error of three 
repeats. C. Comparison of emission averages as calculated over 33 time points (n=33) with SD.  
Statistical comparison of ƛmax was done via One-way Anova and Bonferroni's Multiple Comparison 
Test with a = P<0.01; b, c, d =P<0.001; e = P<0.05. 
 
The emission ƛmax of different formulations of Trc mix differed between the two 
concentrations of 50 and 6.25 µg/mL (Figures 4.7 and 4.8C). The emission ƛmax at 50 µg/mL 
Trc mix is red-shifted when compared to 6.25 µg/mL of Trc mix (Figure 4.8C). This indicated 
that the Trp residues were in a more polar environment in the structures that formed at 50 
µg/mL than those that exist at 6.25 µg/mL of Trc mix. The redshift and the quenching that 
were observed would be correlated if there is an interaction of some of the Trp side chains 
with the polar residues of the peptide in the oligomers. There is a blue shift for 6.25 µg/mL 






































































































control. This indicated that the Trp residues are in a more hydrophobic environment as A4M 
is a methylated cellulose and the most hydrophobic formulant. 
Monitoring of Trp fluorescence over a broader concentration range of Trc mix and formulated 
Trc mix revealed the critical concentration in which Trp environment changes, which would 
be related to the critical concentration of oligomerisation/aggregation. The relation of the 
initial changes and oligomerisation over the first 60 minutes was investigated by measuring 
the total Trp fluorescence over a biological concentration range (100 to 1.25 µg/mL) of Trc 
mix and formulated Trc mix. From this, it was again shown that Trc mix concentration has a 
major influence on oligomerisation behaviour (Figure 4.8). Formation of oligomers takes 
place at high rates with multiple reactions that are far from equilibrium, therefore it was not 
feasible to determine the initial oligomerisation rate for each of the concentrations 11. To 
simplify the analysis, the data from the first 10 minutes were ignored because of large 
fluctuations (low S/N). At a low concentration of Trc mix, total Trp fluorescence is low as 
expected, and errors will be larger. Increasing the concentration of Trc mix will result in 
increased total fluorescence intensity and more reliable readings. However, this depends on 
if the peptide remains in solution and does not oligomerise, which both will lead to quenching 
and influence on the total Trp fluorescence and data reliability. However, the change of Trp 
fluorescence at a specific concentration with the increase in the Trc mix concentration can 
be used to determine the critical oligomerisation concentration as the linear correlation with 
the total fluorescence intensity will be lost. That is because the concentration of Trc mix is 
high enough to result in the formation of large oligomers that can lead to settling out of 
solution (not visible to the naked eye) and/or quenching of Trp fluorescence due to aromatic 
stacking of aromatic amino acid residues (π-π interactions) 1. This can cause a loss in signal 
intensity that depends on the Trc mix concentration and type of side chains present in the 
cellulose derivatives and solvent. The change in the environment of the peptide molecules 
can result in a change in hydrogen bonded structures, weak non-covalent interaction, and 
aromatic amino acid stacking, leading to different critical oligomerisation concentration. 
From these studies, we determined the Trc mix critical oligomerisation concentration of the 
Trp-containing peptide as 8 µg/mL (~ 6 M). The Trc mix formulation with A4M and E4M 
presented critical oligomerisation concentrations as 17 µg/mL (~13 M) and 15 µg/mL (~12 
M) respectively. Therefore, a higher concentration of peptide is needed in the A4M and 
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       Monitoring the influence of formulation on aggregation concentration of Trc mix. A. 
Control, B. A4M and C. E4M. Fluorescence excitation and emission of Trc mix (100-1.25 µg/mL) 
were at 280 and 348 nm, respectively. Three repeats of each preparation are shown via scatter 
dot plots. Continual readings were taken for the first 60 minutes with F60/F10 the reading taken at 
60 minutes/reading taken at 10 minutes. A sigmoidal curve with a variable slope was fitted to each 
of the data sets (R2>0.99) and the intercept between the slope and the plateau was taken as the 



























A more detailed study was done in parallel on the oligomerisation of TpcC utilising 
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    Monitoring the influence of concentration on the aggregation of TpcC. A. Decrease in 
total fluorescence of TpcC at different concentrations over time, B. Comparison of the initial and 
terminal rate of fluorescence decay over the TpcC concentration range C. Oligomerisation onset plot 
of TpcC. Continued readings were taken for the 600 minutes with F180/F10 the reading taken at 180 
minutes/reading taken at 10 minutes. A sigmoidal curve with a variable slope was fitted to the data 
set (R2>0.99) and the intercept between the slope and the plateau was taken as the critical  
oligomerisation concentration. Fluorescence excitation and emission of TpcC (100-3 µM) were at 


























































































The article on this study is has been accepted for publication in Biochimie 15 and we will 
only report in brief on the major findings concerning TpcC oligomerisation monitoring using 
fluorescence. 
The Trp fluorescence investigations of TpcC (ranging from 3-100 µM) proved to be highly 
dependent on two factors namely, time and concentration. Due to the aromatic π-π stacking, 
there is a Trp fluorescence signal quenching for all different concentrations over 600 minutes 
(Figure 4.10A). The initial and the terminal rate of the Trp signal loss differs from one another 
but follows that same trend over the concentration range (Figure 4.10B). Similar to Trc mix, 
lower concentration of TpcC resulted in lower Trp fluorescence signal, while increased TpcC 
concentration resulted in higher Trp fluorescence signal, but it did not show a linear trend 
over the whole concentration range (Fig. 4.10C). The critical oligomerisation concentration 
in which the linear correlation between the TpcC concentration and Trp fluorescence signal 
was lost, was calculated to be 16 µM. (Figure 4.10 C). It is hypothesised that a higher 
concentration of TpcC (above 16 µM or 12 g/mL) results in the formation and settling of the 
large aggregates/oligomers out of the solution, which leads to a decrease in the Trp 
fluorescence signal intensity. Furthermore, high oligomerisation concentration could explain 
cellulose derivatives formulation (A4M) had a limited effect on the TpcC activity against C. 
albicans reported in Chapter 3. Interestingly, in a parallel study done in our group, it was 
found that the oligomerisation concentration for the more hydrophobic TrcA 15 µM 16 or 12 
g/mL, also explaining the lack of influence of A4M and E4M. 
Due to limited access to laboratory facilities in 2020 during COVID-19 lockdown restrictions, 
we were unable to complete the studies on E10M and K15M for Trc mix. However, it can be 
assumed that these two related cellulose polymers will also shift the critical oligomerisation 
concentration and this study will be complete with the formulation studies of the purified 
peptides and the fluorescence studies in a parallel project. 
 
4.5 Conclusions 
Trcs have a pronounced tendency to form oligomers/aggregates 1, 2, 3. Trcs biological activity 
is proposed to be dependent on their oligomerisation, in particular the formation of 
amphipathic dimers that is hypothesised to be the active membrane interacting moieties 5. 
Therefore, Trcs’ loss of propensity to form dimers could result in loss of biological activity. 
However, Trcs oligomerisation is far from equilibrium and they form higher oligomers over a 
longer maturation time. Higher oligomers that are dependent on hydrophobic interactions 
are more stable 14 and will have a lower biological activity because of the limited solubility
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and lower release of active dimers. Oligomerisation also results in more technical difficulties 
when handling the peptide, leading to variable results. By formulation of Trc with cellulose 
derivatives, we aimed to control the rate of the oligomerisation. 
This study showed that the formation of Trc mix oligomers is highly dependent on three main 
factors, namely formulant, time and concentration. Higher concentrations of Trcs will form 
higher oligomers over prolonged maturation time 14. By formulation of Trc mix with cellulose 
derivatives, we aimed to control the oligomerisation profile in three main ways, namely by 
choosing the optimal cellulose-derived formulant to limit unwanted oligomerisation, find the 
best ratio of peptide: formulant for stabilisation and finding an optimal maturation time. 
It was found that formulations of Trc mix with various cellulose derivatives stabilise and curb 
the oligomer formation in solution, but that the viscosity of the formulant may play a role. As 
cellulose derivatives could result in the formation and stabilisation of smaller oligomers and 
they prevent the formation of large oligomers and rearrangement of these oligomers. Our 
cellulose formulations, therefore, resulted in lowering the fluorescence scattering of Trc mix, 
even after prolonged maturation. Furthermore, the total Trp fluorescence loss over 20 hours 
of maturation was lower for cellulose derivatives formulations of Trc mix when compared to 
the Trc mix control containing 1.5% ethanol. A higher concentration/ratio of cellulose 
derivative resulted in lower scattering, thus further stabilisation and less Trp fluorescence 
loss over 20 hours of maturation. One interesting aspect that came to the fore is that more 
stable 1:2 and 1:4 formulations did not lose activity against C. albicans as was found for the 
low viscosity formulants CHS, KLUE and KLUL. This indicated that the resultant solution 
conformation of the peptides was optimal to remain active. Furthermore, more viscous 
cellulose derivatives containing the methyl side chain, A4M, E4M, E10M and K15M had the 
better ability of stabilisation which corresponded with lower IC50/MIC values reported in 
Chapter 3. 
Cellulose derivatives changed the environment of the Trp residues leading to a change in 
fluorescence and therefore may have also changed the peptide conformation in solution. 
Although cellulose derivatives did not change the rate of the peptide oligomerisation 
(∆RFU/minute over 12-60 minutes), they did influence the emission ƛmax of formulated Trc 
mix at 50 and 6.25 µg/mL. A4M preparation of Trc mix at (50 and 6.25 µg/mL) had a lower 
ƛmax compared to control and other cellulose derivatives possibly because it creates a more 
hydrophobic environment. Furthermore, all the formulations with 50 µg/mL Trc mix had 
higher ƛmax values which could be due to the exposure of the Trp residue to polar side chains 
in the oligomer structure. The stacking of aromatic amino acid residues caused quenching, 
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combined with a blue shift in all the formulations from the expected ƛmax of 350 nm of Trp, to 
between 336 nm and 342 nm. 
It was observed that the cellulose derivatives decrease the critical oligomerisation 
concentration of Trc mix, possibly by direct interaction and chaotropic activity. The methyl 
side chains present within the cellulose derivatives structure can increase the hydrophobicity 
of the formulation resulting in lowering the oligomerisation of Trcs driven by hydrophobic 
clustering. Although higher concentration results in the formation of higher oligomers, upon 
addition of cellulose derivatives at a 1:4 peptide: formulant ratio, the critical oligomerisation 
concentration changed drastically from 8 µg/mL for Trc mix alone to 15 µg/mL and 17 µg/mL, 
in A4M and E4M formulations, respectively. The higher concentration of cellulose derivatives 
could stabilise the formulants, as the presence of more saccharide molecules were able to 
interact with more Trcs molecules and lower the water activity, thereby reducing the 
hydrophobic forces. Furthermore, more concentrated formulations were better stabilised 
over 20 hours of maturation and did not increase the data scattering that is linked to 
instability. The higher TpcC concentration that was found for the critical oligomerisation 
concentration of the purified TpcC could explain, the reason that A4M formulation had a 
limited effect on this peptide’s activity (refer to Chapter 3). Conversely the more hydrophobic 
and more active peptide, TrcA showed minor activity loss in formulation with A4M and E4M 
(refer to Chapter 3). Therefore, it is hypothesised that there is an optimal oligomer size in 
the solution that is important for the biological activity of the peptide. Some of these 
oligomers may have been disrupted by the formulations. Another possibility for lower activity 
of formulated TrcA is that its target interaction groups were masked by interaction with the 
glucose moieties, as described by Juhl et al.4. TrcA is one of the most abundant peptides 
present the Trc mix that forms hetero-oligomers. 
In conclusion, the cellulose derivatives successfully stabilised the Trc mix formulations 
resulting in lower Trp fluorescence signal loss. higher critical oligomerisation concentrations 
and more stable solution-phase oligomers that maintained biological activity. Therefore. it is 
concluded that cellulose derivatives prevent or slow down the formation of Trc mix oligomers 
over prolonged incubation time which consequently increase the biological activity of Trc 
mix against Candida species. However, much more development and optimisation are still 
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4.7 Supplementary data 
Table S1 Summary of the Trp fluorescence in RFUs of different preparations/formulations of Trc 
mix after 1, 4 and 20 hours of maturation. 
 
 Fluorescence ± SD (n=12)  
 Trc mix:    
Formulant formulant 
(m/m) 
1 hour 4 hours 20 hours 
Control - 5539 ± 4481 3347±1261 2345±1584 
A4M 1:1 5844 ± 280.6 
3347±1463 
3839 ± 449.5 
E4M 1:1 6087±865.1 
4517±1351 
4443 ± 454.1 
E10M 1:1 5244±978.7 
4822±1107 
3511 ± 338.6 
K15M 1:1 7130±903.2 
3951±1211 
5133 ± 325.9 
A4M 1:2 8628±1340 
5653±1260 
8087 ± 369.5 
E4M 1:2 8846±1122 
7744±1212 
8409 ± 347.6 
E10M 1:2 9154±1029 
8554±976.1 
8361 ± 263.8 
K15M 1:2 6413 ± 1729 
8663±943.2 
6291 ± 214.5 
A4M 1:4 5910 ± 179.9 
6249±577.6 
5381±646.8 
E4M 1:4 6850 ± 144.7 
5488±453.5 
6326±516.9 
E10M 1:4 7120 ± 155.1 
6632±455.6 
6443±518.0 




Table S2 Statistical comparison of Trp fluorescence between different Trc mix of fresh (1h) 
and matured (20h) preparations. Tabulated Trp fluorescence represents the mean 12 
preparations with SD. Unpaired Student t-test was done on each of the analysed pairs. 
 
 Fresh sample (1 
hour) mean ± 
SD 
Matured sample (20 
hours) mean ± SD 
P-value 
Trc mix: cellulose derivatives 1 1 (m/m) 
A4M 5844±72.0 3839±1557 0.0010 
E4M 6087 ± 249.7 4443±1573 0.0044 
E10M 5244 ± 282.5 3511±1173 0.0007 
K15M 7130 ± 260.7 5133±1129 <0.0001 
Trc mix: cellulose derivatives 1 2 (m/m) 
A4M 8628 ± 386.8 8087±1280 ns 
E4M 8846 ± 323.9 8409±1204 ns 
E10M 9154 ± 297.0 8361±913.9 ns 
K15M 6413 ± 499.1 6291±743.2 0.0093 
Trc mix: cellulose derivatives 1 4 (m/m) 
A4M 5910±623.3 5381±646.8 ns 
E4M 6850±501.1 6326±516.9 ns 
E10M 7120±537.2 6443±518.0 ns 
K15M 7335±401.6 6392±373.6 ns 
Control 5539 ± 4481 2345±1584 0.0277 
Stellenbosch University https://scholar.sun.ac.za
4-25  
Table S3 Statistical comparison Trp fluorescence between different preparations at 1 4 and 20 hours of 
Trc mix. Tabulated Trp fluorescence represents the mean of 12 preparations with SD. One-way Anova 
with Bonferroni correlation test was done between each of the selected data sets groups. 
 
 1 hour of maturation 
 1:4 1:2 1:1  


























K15M ns ns ns ns ns <0.05 ns ns ns ns 0.001 ns 
E10M ns ns ns ns <0.01 ns ns ns ns ns ns 
E4M ns ns ns 0.001 ns ns ns ns ns ns 
A4M  ns ns 0.001 0.001 ns ns ns ns ns 





ns ns ns ns ns 
E10M <0.05 ns 0.001 0.001 0.001 
E4M ns ns 0.001 0.001 0.001 
A4M ns ns <0.01 0.001 0.001 
K15M          ns ns ns ns 
E10M           ns ns <0.05 
E4M            ns ns 
A4M             ns 
 4 hours of maturation 
 1:4 1:2 1:1  


























K15M ns ns ns ns ns ns ns ns 0.001 ns <0.05 0.001 
E10M ns ns ns <0.05 <0.05 ns ns 0.001 ns <0.05 0.001 
E4M ns ns <0.05 <0.05 ns ns 0.001 ns <0.05 0.001 
A4M  <0.05 0.001 0.001 ns ns ns ns ns <0.05 
K15M      <0.01 <0.01 ns ns <0.01 ns ns 0.001 
E10M       ns ns 0.001 0.001 0.001 0.001 0.001 
E4M        ns 0.001 0.001 0.001 0.001 0.001 
A4M         <0.05 0.001 0.001 0.001 0.001 
K15M          ns ns ns <0.01 
E10M           ns ns ns 
E4M            ns ns 
A4M             ns 
 20 hours of maturation 
 1:4 1:2 1:1  



























K15M ns ns ns ns ns ns ns ns 0.001 ns <0.01 0.001 
E10M ns ns ns ns ns ns ns 0.001 ns 0.001 0.001 
E4M ns ns ns <0.05 ns ns 0.001 <0.05 <0.01 0.001 
A4M  ns ns 0.001 0.001 ns ns 0.001 ns 0.001 
K15M      ns <0.05 ns ns 0.001 ns <0.01 0.001 
E10M       ns ns 0.001 0.001 0.001 0.001 0.001 
E4M        ns 0.001 0.001 0.001 0.001 0.001 
A4M         0.001 0.001 0.001 0.001 0.001 
K15M          ns ns ns 0.001 
E10M           ns ns ns 
E4M            ns <0.05 
A4M             ns 
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Table S4 Statistical comparison of Trp signal loss from 1 to 4 hours and 1 to 20 hours of maturation between 
different preparations of Trc mix. The values utilised were the mean 12 preparations with SD. One-way 
Anova with Bonferroni correlation test was done between each of the selected data sets groups. 
 
 Signal loss from 1 to 20 hours of maturation 
 1:4 1:2 1:1  


































K15M ns ns ns ns ns ns ns ns ns ns ns ns <0.05 
E10M ns ns ns ns ns ns ns ns ns ns ns ns <0.01 
E4M ns ns ns ns ns ns ns ns ns ns ns ns 0.001 




K15M ns ns ns ns ns ns ns ns ns ns ns ns 0.001 
E10M ns ns ns ns ns ns ns ns ns ns ns ns <0.01 
E4M ns ns ns ns ns ns ns ns ns ns ns ns <0.01 




K15M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns ns ns ns ns 
A4M ns ns ns ns ns ns ns ns ns ns ns ns ns 
 Control ns ns ns ns ns ns ns ns ns ns ns ns ns 
 Signal loss from 1 to 4 hours of maturation 
 1:4 1:2 1:1  








































K15M ns ns ns ns ns ns ns ns ns ns 0.001 ns 
E10M ns ns ns ns ns ns ns ns ns ns ns 
E4M ns ns ns ns ns ns ns ns ns <0.05 
A4M  ns ns ns ?? ns ns ns ns <0.05 
K15M      ns ns ns ns ns ns ns <0.01 
E10M       ns ns ns ns ns ns ns 
E4M        ns ns ns ns ns <0.05 
A4M         ns ns ns ns ns 
K15M          ns ns ns ns 
E10M           ns ns ns 
E4M            ns ns 
A4M             ns 
 Signal loss from 1 to 20 hours of maturation 
 1:4 1:2 1:1  









































K15M ns ns ns ns ns ns ns ns ns ns ns ns 
E10M ns ns ns ns ns ns ns ns ns ns <0.05 
E4M ns ns ns ns ns ns ns  ns <0.01 
A4M  ns ns ns ns ns ns ns <0.01 
K15M      ns  ns ns ns ns ns <0.05 
E10M       ns ns ns ns ns ns <0.01 
E4M        ns ns ns ns ns <0.01 
A4M         ns ns ns ns <0.01 
K15M          ns ns ns ns 
E10M           ns ns ns 
E4M            ns ns 




Conclusions and future studies 
 
5.1. Introduction 
An increasing number of immunocompromised people have resulted in an increase in fungal 
infections. In addition, the limited number of available antifungal drugs has resulted in 
antifungal drug resistance 1, 2, 3. Furthermore, the rapid development of resistance towards 
antifungal drugs and difficulties in new drug development has become a global problem 4. 
The tyrocidines (Trcs) and the analogues, as small non-ribosomal antimicrobial peptides 
with proven anti-Candida activity 5 were chosen for this study. Trcs are interesting to study 
further as a potential novel generation of antifungal drugs. We tested the biological activity of 
Trcs against two of the most common human fungal pathogens namely Candida albicans 
and C. glabrata. As the relation of Trcs self-assembly structures and their activity was 
previously reported 6, 7, we decided to manipulate their oligomerisation via formulation. The 
formulants chosen for this study were cellulose derivatives containing methyl and ethyl side 
chains. The reason for this choice was the ability of Trcs to interact with the OH group of 
glucose which was previously reported 8. We aimed to investigate the influence of the other 
side chains of cellulose derivatives on the Trc activity 9. The self-assembly of the Trcs was 
monitored via fluorescence spectrometry as 4 out of 10 amino acid residues present within 
the Trc structure are good fluorophores. Furthermore, we attempted to stabilise the 
oligomerisation of Trcs, which could lead to loss of the biological activity, via formulation. 
Trcs oligomerisation profile is dynamic with a constant arrangement and rearrangement of 
the oligomers. Addition of cellulose derivatives to the Trcs aimed to curb the formation of the 
oligomers and stabilise the Trcs active moieties. Finally, we compared the anti-Candida 
activity of the Trcs their cellulose type formulations with two of the anti-Candida compounds 
available on the market namely, fluconazole and caspofungin 10, 11. The environmental C. 





5.2.1. Production and purification of single Trc analogues 
The production and purification of five Trcs single analogues namely, TrcA, TrcB, TrcC, 
TpcB and TpcC was successfully achieved. All five analogues had a purity of higher than 
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90%. This aim was achieved through four main steps, namely, manipulated bacterial 
production of the tyrothricin complex using the soil bacterium Br. parabrevis 8185, organic 
extraction of the tyrothricin complex from the bacterial culture, removal of gramicidins (Grms) 
and non-peptide material and extraction of the Trcs and analogues. In the case of 
commercial tyrothricin, removal of Grms was the only necessary step. Linear Grms and non- 
peptide material as well as certain Trcs and analogues were removed at each step of the 
extraction and purification. As an example, although the DEE-acetone precipitation step 
resulted in the removal of all linear Grms from the non-supplemented crude extract of the 
tyrothricin complex, it caused major loss of TrcA during this step. 
As part of this project focused on studying the biophysical behaviour of Trcs single analogue, 
high purity of each of the analogues was needed. RP-HPLC was utilised to isolate each of 
the Trcs single analogues with high purity. Isolation of Trcs single analogues with a purity of 
higher than 90% is a complicated task as Trcs have a great tendency of oligomerisation 12. 
Trcs aggregation/oligomerisation results in peak broadening and inconsistent retention time, 
making RP-HPLC purification difficult. As an example, the retention time of Trc A1/A, B1/B, 
and C1/C (from 6-hours matured commercial tyrothricin complex) was 2-3 minutes later than 
the fresh sample. By loading a lower concentration, as the peptide became purer onto the 
RP-HPLC system, and collecting all the HPLC fractions manually, these difficulties were 
averted. Furthermore, the purification of certain analogues was eased via supplementation of 
Br. parabrevis cultures via 20 mM Phe and 10 mM Trp. The amino acid supplementation with 
Phe and Trp of the culture successfully shifted the production towards TrcA and TpcC, 
respectively. Phe-supplementation proved to decrease the Grms production while Trp-
supplementation increased Grms production, but also increased the production of the Trp 
containing peptides such as TrcC and TpcC. These results correlated with previous findings 
13. 
5.2.2. The biological activity of the Trcs 
Anti-Candida activity of Trc mix and single Trc analogues 
 
In general, Trcs showed promising activity against both C. albicans and C. glabrata. This is 
specifically very important, as the C. albicans strain studied in this project, proved to be 
resistant towards caspofungin and fluconazole while C. glabrata is inherently resistant 
towards fluconazole 14. Furthermore, comparison of the anti-Candida activity of TrcA, Trc mix 
and TpcC with that of fluconazole and caspofungin, it was observed that exposure to the 
Trcs result in far less induction of a metabolic stress response. This type of stress response 
of the Candida cells can ultimately lead to resistance as well as biofilm formation. 
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As eradication of biofilms is drastically more tedious than the eradication of planktonic cells, 
the fact that Trcs resulted in a lower level of the stress response and possible biofilm 
formation, is of importance. Furthermore, the stress response is the first step for the 
activation of signals which leads to expression of multidrug-resistant pumps to keep the anti-
fungal compound out of the cells 15. This means that there is a significantly smaller chance 
that Candida cells develop a resistance mechanism against Trcs due to rapid and multiple 
modes of action. 
Another interesting point which came to the fore was the influence of Trc formulation 
maturation time on the anti-Candida activity. While maturation time enhanced the Trc mix 
activity toward C. albicans, it did not significantly influence the activity of either TrcA or TpcC. 
It must be noted that Trc mix contains a complex mixture of different analogues, mainly 
including Trc A1/A, B1/B, and C1/C. It is possible, that longer incubation is needed to form 
stable hetero-oligomers that has high activity towards Candida cells. Alternatively, longer 
maturation (20 hours) of Trc mix may have resulted in heterooligomers that supported the 
release of more amphipathic dimers in the solution and therefore enhanced the activity. It is 
hypothesised that the highly active TrcA, which is one of the most hydrophobic Trcs, has a 
relatively stable oligomer and dimer population in solution, therefore longer maturation time 
was an ineffective factor in TrcA biological activity enhancement. TpcC on the other hand is 
a more polar peptide analogue but it has inherently lower activity against C. albicans and 
formulation or longer maturation also did not enhance the activity. Furthermore, parallel 
research showed that TpcC forms large oligomers/ aggregates 16. Longer maturation time 
did not result in the rearrangement of the oligomers with the more release of active 
amphipathic dimers or oligomers. 
Effect of cellulose derivatives on the anti-Candida activity of Trcs 
 
Selected concentrations of Trc mix were formulated by seven different cellulose derivatives, 
these formulations differed from one another in viscosity and side chains. The formulation 
of Trc mix by high viscous cellulose derivatives significantly increased the anti-Candida 
activity of the peptide. Two out of 24 treated Candida cultures by 50 µg/mL Trc mix alone 
survived, while none survive when Trc mix was formulated. As expected, the survival of 
cultures increased as they were treated by lower concentrations of Trc mix such as 25 and 
12.5 µg/mL. This difference in survival could be due to the presence of Candida persister 
cells 15. We chose the formulants that were generally better to eradicate both populations of 
persister and normal Candida cells. The formulations in low viscous cellulose derivatives 
such as KLUE and KLUI, in addition to CHS did not enhance the Trc mix activity. The more 
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viscose formulants of Trc mix such as (A4m, E4M, E10M and K15) seemed to have a better 
anti- Candida activity. When Trc mix was formulated by an increased concentration of 
selected cellulose derivatives, it improved the stability while activity was maintained. For all 
the formulations, Trc mix formulated by E10M 1:4 (m/m) significantly had better anti-Candida 
activity compared to the control. Furthermore, when C. glabrata cultures were treated by 
different preparations of matured Trc mix, they showed good activity, but the activity of Trcs 
towards C. albicans was better compared to C. glabrata. 
Although cellulose derivatives enhanced the anti-Candida activity of Trc mix they did not 
significantly influence the anti-Candida activity of the purified TrcA and TpcC. This 
ineffectiveness can be due to the stability of TrcA oligomers or inherit lower anti-Candida 
activity of the more polar and bulkier TpcC. Cellulose derivatives generally did not result in 
the rearrangement or stabilisation of TrcA or TpcC oligomers to enhance the anti-Candida 
activity. 
 
5.2.3. Investigation of the stability of Trcs utilising fluorescence 
In this study, it was aimed to both enhance the activity and solution stability of the Trcs via 
formulation. Overall, this aim was successfully achieved through the formulation of Trcs via 
cellulose derivatives. Stability of the drugs is an extremely important factor to consider in 
drug discovery and development. While the term drug stability refers to the extent in which a 
drug formulant retains its potency, physical and chemical characteristics during storage and 
use, in this study, the stability of the formulation referred to a wider definition. 
Part of the creation of stable Trc formulant is to control the unwanted oligomerisation of Trcs. 
Trcs tend to oligomerise, especially at higher concentrations12. As Trcs oligomerisation is 
far from equilibrium, they form higher oligomers over a longer maturation time. The 
interaction of cellulose derivatives and Trc mix was observed to slow the formation of 
unwanted Trcs oligomers. The stability of these formulations was monitored via Trp 
fluorescence scattering. A formulation of Trc mix which showed less scatter over 20 hours 
of maturation time had better stability, while the aggregation/oligomerisation is supported by 
the lower total fluorescence or quenching at 20 hours versus 1 hour of maturation. It was 
found that the formulation of Trc mix by seven different cellulose derivatives successfully 
stabilised the Trc solution structures and oligomerisation in aqueous solution over 20 hours 
of maturation. This stability resulted in the lower scattering of Trp fluorescence signal and 
Trp fluorescence signal quenching over 20 hours of maturation. The cellulose derivatives 
formulant of Trc mixed differed in the side chain and viscosity, interestingly enough, the most 
stable formulations in terms of Trp fluorescence contained CHS and K15M, followed by 
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KLUE and KLUL. However, these low viscose formulants, KLUE, KLUL and CHS, did not 
enhance the Trc mix anti-Candida activity. It seems that highly stable oligomers may not 
have a high enough affinity to bind to the cell membrane of Candida cells. Another possibility 
is that the cellulose derivatives of low viscosity might mask the active groups in the peptide 
oligomers. 
When Trc mix was formulated by the higher concentration of A4M, E4M, E10M and K15M, 
it was found that a higher concentration/ratio of cellulose derivative resulted in lower 
scattering and Trp fluorescence loss over 20 hours of maturation. However, 1:2 and 1:4 
(m/m) of cellulose derivatives Trc mix showed better anti-Candida activity. This meant that 
unlike low viscous formulations of Trc mix, at the higher ratio of A4M, E4M, E10M and K15M, 
the resultant solution conformation of the peptides was optimal to remain active. 
When the effect of time on the oligomerisation of Trcs mix was further investigated, it was 
found that there was a major Trp fluorescence loss was over the first six minutes of 
maturation for Trc mix in control solution and in A4M at 1:4 (m/m). This was an indication of 
rapid conformational rearrangement of Trc oligomers. However, once again when the 
peptide was formulated by a low viscous solution (in this case E4M), the large fluorescence 
loss did not occur indicating that Trc mix formulated in cellulose derivatives with low viscosity 
are more stable formulant compared to high viscosity cellulose derivatives. 
When we measured the rate in which the oligomerisation took place, it was found that 
concentration is a major factor on the oligomerisation rate. Monitoring of Trp fluorescence 
over a broader concentration range of Trc mix and formulated Trc mix revealed that the 
formulants changed the critical concentration in which Trp environment changes, which 
would be related to the critical concentration of oligomerisation/aggregation. It was 
determined that the Trc mix critical concentration of oligomerisation was 8 µg/mL (~6 M), 
while this concentration was higher for formulated Trc mix. The Trc mix formulations with 
A4M and E4M presented a critical concentration of oligomerisation as 17 µg/mL (~13 M) 
and 15 µg/mL (~12 M), respectively. The critical oligomerisation concentration can relate 
to the biological activity of the peptide. Trc mix in control solution has lower activity as the 
oligomerisation concertation is lower leading to unwanted oligomerisation, while formulated 
Trc mix has higher activity as the oligomerisation concertation is higher more active moieties 
are available at lower concentrations. 
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5.3. Future studies 
This project was the first exploratory study on cellulose derivatives formulation of Trcs with 
anti-Candida activity and must be expanded to test more purified Trcs peptides and different 
formulations, such as lipid-type formylations. A previous study has shown that lipid- 
formulation significantly decreased the haemolytic activity of Trcs 17. However, a preliminary 
study on the anti-Candida activity of Trc mix formulated cholesterol sulphate (CS), showed 
that this formulation of the Trc mix makes it inactive against C. albicans. This could be due 
to the similarity between cholesterol and ergosterol in the fungal membrane, with ergosterol 
possibly one of the targets of the Trcs. CS can compete for this interaction and lead to the 
loss of affinity towards binding the cell membrane. Besides human erythrocytes, it is 
recommended to test the toxicity of the formulations of Trcs against a vaginal cell line to 
assess the potential for topical application to combat vaginal candidiasis. 
It would be beneficial to the fluorescence studies tracking the critical concentration of 
oligomerisation for more formulations and ratios, especially for the most promising formulant 
E10M, as well as K10M and the less viscous formulants KLUL and KLUE. This will clarify 
the influence of the formulants on the critical concentration of oligomerisation of the Trc 
peptides in relation to viscosity, stability, and activity. The fluorescence study on TpcC was 
only done in 20% acetonitrile in water and can be expanded to TpcC in 1.5% ethanol: water 
and formulated TpcC, to determine the oligomerisation concertation of TpcC when 
formulated by cellulose derivatives. 
 
5.4. Last word 
The environmental Candida strain was isolated from Eerste River in Stellenbosch. This river 
flows through the neighbourhood surrounding Stellenbosch in which people do not have 
access to clean piped water and as a result, they use the river water to cook, clean and to 
do other daily chores. A large number of people in these areas are immunocompromised 
suffering from diseases such as HIV and tuberculosis (TB). Many TB and HIV patients also 
suffer from recurring fungal infections. By using the river water, they are exposed to Candida 
contamination which can be deadly for the immunocompromised individuals. Furthermore, 
the lack of access of the residents of these areas to the medical health care is concerning. 
Previous research has shown the ability of the Trcs to attach to the cellulose-based materials 
while remaining active against pathogenic bacteria 19. This relates well to this study that 
shows the stabilisation of anti-Candida activity in the presence of cellulose derivatives. 
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Combining the previous research with the research in this study, cellulose type filters with 
Trcs could be used to treat the river water to eliminate Candida and other possible 
pathogenic bacteria and fungi. Trcs broad-spectrum activity and safety while consumed 
orally benefits the practicality of this proposal 20. This study could therefore benefit 
compromised communities in the future, particularly because the production of the peptides 
is economical, and treatment of cellulose type filters would be relatively easy. 
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